

## **INFORMATION TO USERS**

**The most advanced technology has been used to photograph and reproduce this manuscript from the microfilm master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while others may be from any type of computer printer.**

**The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affect reproduction.**

**In the unlikely event that the author did not send UMI a complete manuscript and there are missing pages, these will be noted. Also, if unauthorized copyright material had to be removed, a note will indicate the deletion.**

**Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning the original, beginning at the upper left-hand corner and continuing from left to right in equal sections with small overlaps. Each original is also photographed in one exposure and is included in reduced form at the back of the book.**

**Photographs included in the original manuscript have been reproduced xerographically in this copy. Higher quality 6" x 9" black and white photographic prints are available for any photographs or illustrations appearing in this copy for an additional charge. Contact UMI directly to order.**

# **U·M·I**

University Microfilms International  
A Bell & Howell Information Company  
300 North Zeeb Road, Ann Arbor, MI 48106-1346 USA  
313/761-4700 800 521-0600

**Order Number 9119627**

**Corticotropin-releasing hormone regulation of immunoreactive  
beta-endorphin secretion in Leydig cells in the rat testis**

**Eskeland, Nahida Lucia, Ph.D.**

**City University of New York, 1991**

**Copyright ©1991 by Eskeland, Nahida Lucia. All rights reserved.**

**U·M·I**  
300 N. Zeeb Rd.  
Ann Arbor, MI 48106

## **NOTE TO USERS**

**THE ORIGINAL DOCUMENT RECEIVED BY U.M.I. CONTAINED PAGES WITH  
PHOTOGRAPHS WHICH MAY NOT REPRODUCE PROPERLY.**

**THIS REPRODUCTION IS THE BEST AVAILABLE COPY.**

A

**CORTICOTROPIN-RELEASING HORMONE REGULATION OF  
IMMUNOREACTIVE BETA-ENDORPHIN SECRETION IN  
LEYDIG CELLS IN THE RAT TESTIS**

**Nahida Lucia Eskeland**

**A dissertation submitted to the Graduate Faculty in  
Biomedical Sciences in partial fulfillment for the  
degree of Doctor of Philosophy, The City University of  
New York.**

**1991**

© 1991

**NAHIDA LUCIA ESKELAND**

**All Rights Reserved**

**This manuscript has been read and accepted for the Graduate Faculty in Biomedical Sciences in satisfaction of the dissertation requirement for the degree of Doctor of Philosophy.**

1/15/91  
Date

Beth S. Schachter  
Beth S. Schachter, Ph.D.  
Chair of Examining Committee

1/15/91  
Date

Terry A. Krulwich  
Terry A. Krulwich, Ph.D.  
Executive Officer

James L. Roberts, PhD

Ravi Iyengar, PhD

\_\_\_\_\_  
Supervisory Committee

The City University of New York

**ABSTRACT****CORTICOTROPIN-RELEASING HORMONE REGULATION  
OF IMMUNOREACTIVE BETA-ENDORPHIN SECRETION IN  
LEYDIG CELLS IN THE RAT TESTIS**

by

Nahida Lucia Eskeland

Advisor: Beth S. Schachter, Ph.D.

Corticotropin-releasing hormone (CRH), a hypothalamic peptide, is the principal stimulator of pro-opiomelanocortin (POMC) synthesis and secretion in the pituitary gland. POMC and CRH syntheses have been documented in other tissues such as the testis, but a possible regulatory action of CRH on POMC in the testis was unknown. Therefore the current study evaluated various aspects of CRH action on POMC peptide secretion from testicular cells. CRH stimulated secretion of  $\beta$ -endorphin ( $\beta$ EP, a POMC peptide) from a subset population of Leydig cells in culture. The secretagogue acted in a dose-dependent fashion and was inhibited by a CRH competitive antagonist, demonstrating that POMC-producing Leydig cells have functional CRH receptors. Moreover, we have shown that CRH stimulated ir $\beta$ EP levels in testicular interstitial fluid in the intact testis of pubertal but not adult rats. These data suggest a physiological and developmental function for CRH in the testis.

Only short POMC-like transcripts that are missing the amino terminal signal-peptide

coding region have been reported in the rat testis. Using polymerase chain reaction, a full length pituitary-like POMC mRNA was detected in the rat testis, showing that the rat testis has a POMC transcript capable of encoding a prohormone that can go through processing, packaging and secretion pathway for regulated secretory peptides.

The effect of two physiologically relevant temperatures on the CRH/POMC system was analyzed since testicular function is known to be sensitive to thermal changes. At 34°C, CRH dose-response curves for both TM3 (a mouse Leydig cell-line) and AtT20 (a mouse pituitary cell-line) had significantly lower  $EC_{50}$ s than at 37°C. These studies suggest that CRH receptors or post receptor mechanisms may be sensitive to temperature changes.

Finally, possible source(s) of CRH synthesis in the rat testis was investigated. Using non-radioactive *in situ* hybridization on adult testis sections, CRH mRNA was detected predominantly in germ cells, suggesting that these cells may be a major source of CRH.

## **ACKNOWLEDGEMENT**

If it were not for the following persons, I would not be writing this thesis: I would like to thank my thesis advisor Dr. Beth Schachter for her guidance and support during my graduate studies. In addition, I would like to extend my heartfelt gratitude to Drs. James Roberts, Ravi Iyengar and Christopher Molineaux for their encouragement and positive input on my research. I would also like to thank the following persons for their help in making my experiments more feasible and productive:

**Dr. Dennis Healy**

**Dr. Sandy Masur**

**Miriam Bender-Birge**

**Ed Ravano**

**Arturo Chaparro**

## **FORMAT OF THESIS**

**This thesis is prepared according to the new guidelines of the City University of New York which permit the direct incorporation of published research articles as chapters. The thesis has an abstract, table of contents, general introduction, chapters, a general discussion, appendix and bibliography. Each chapter contains an abstract, a specific introduction, material and methods, results, discussion, tables and figures, and discussion. Copyright permission for the published chapter was obtained from the respective publisher.**

## **TABLE OF CONTENTS**

|   |             |
|---|-------------|
| <b>ABSTRACT</b> .....   | <b>iv</b>   |
| <b>ACKNOWLEDGEMENT</b> .....  | <b>vi</b>   |
| <b>FORMAT OF THESIS</b> .....   | <b>vii</b>  |
| <b>LIST OF TABLES</b> .....   | <b>xiii</b> |
| <b>LIST OF FIGURES</b> .....  | <b>xiv</b>  |
| <br>  |             |
| <b>I. GENERAL INTRODUCTION</b> .....  | <b>1</b>    |
| <b>A. Paracrine regulation in the testis</b> .....  | <b>1</b>    |
| <b>B. Brief background on POMC and CRH</b> .....  | <b>3</b>    |
| <b>C. POMC messenger ribonucleic acid (mRNA) in the testis</b> .....  | <b>4</b>    |
| <b>D. POMC-derived peptide and CRH function in the testis</b> .....   | <b>6</b>    |
| <b>E. Developmental regulation in the testis</b> .....  | <b>8</b>    |
| <b>F. Temperature changes and chryptorchidism</b> .....   | <b>9</b>    |
| <b>G. Specific aims</b> .....   | <b>11</b>   |
| <br>  |             |
| <b>II. STIMULATION OF IR<math>\beta</math>-ENDORPHIN SECRETION BY<br/>CORTICOTROPIN-RELEASING HORMONE IN PRIMARY RAT LEYDIG<br/>CELL CULTURES</b> ..... | <b>12</b>   |
| <b>1. ABSTRACT</b> .....  | <b>13</b>   |
| <b>2. INTRODUCTION</b> .....  | <b>14</b>   |

|  |           |
|--|-----------|
| <b>3. MATERIALS AND METHODS</b> .....  | <b>16</b> |
| <b>3.1 Chemicals</b> .....   | <b>16</b> |
| <b>3.2 Antisera</b> .....  | <b>16</b> |
| <b>3.3 Animals, cell dispersion, and purification</b> .....  | <b>17</b> |
| <b>3.4 RHPA</b> .....  | <b>18</b> |
| <b>3.5 Immunocytochemistry</b> .....   | <b>19</b> |
| <b>3.6 Quantitative analysis</b> .....   | <b>20</b> |
| <b>4. RESULTS</b> .....  | <b>22</b> |
| <b>4.1 The rate of plaque formation on ir<math>\beta</math>EP-producing cells in<br/>        the presence or absence of CRH</b> .....            | <b>22</b> |
| <b>4.2 Monoclonal antibodies specific to Leydig cell surface<br/>        antigen</b> .....   | <b>22</b> |
| <b>4.3 CRH dose-response curves in the presence or absence<br/>        of CRH-(9-41)</b> .....   | <b>27</b> |
| <b>5. DISCUSSION</b> .....   | <b>36</b> |
| <br>   |           |
| <b>III. CORTICOTROPIN-RELEASING HORMONE STIMULATION OF<br/>    <math>\beta</math>-ENDORPHIN SECRETION IN THE RAT TESTIS <i>IN VIVO</i></b> ..... | <b>40</b> |
| <b>1. ABSTRACT</b> .....   | <b>41</b> |
| <b>2. INTRODUCTION</b> .....   | <b>43</b> |
| <b>3. MATERIALS AND METHODS</b> .....  | <b>45</b> |
| <b>3.1 Chemicals and supplies</b> .....  | <b>45</b> |

|  |    |
|--|----|
|  | x  |
| 3.2 Animals, surgical procedure and treatment .....  | 45 |
| 3.3 Extraction and radioimmunoassay .....  | 46 |
| 3.4 RNA isolation, reverse transcription (RT)<br>and polymerase chain reaction (PCR) ..... | 48 |
| 3.5 Riboprobe synthesis .....  | 49 |
| 3.6 Southern transfer and filter hybridization .....                                       | 49 |
| 3.7 Statistical analysis .....   | 49 |
| 4. RESULTS .....   | 51 |
| 4.1 The effect of CRH on ir $\beta$ EP levels in TIF<br><i>in vivo</i> .....               | 51 |
| 4.2 Pituitary-like POMC mRNA in the rat testis .....                                       | 58 |
| 5. DISCUSSION .....  | 62 |

|   |    |
|---|----|
| IV. THE EFFECT OF TEMPERATURE ON THE ACTION OF CRH ON<br>IR $\beta$ EP SECRETION IN TWO CELL LINES: TM3 AND AtT20 ... | 66 |
| 1. ABSTRACT .....   | 67 |
| 2. INTRODUCTION .....   | 68 |
| 3. MATERIALS AND METHODS .....  | 70 |
| 3.1 Chemicals and supplies .....  | 70 |
| 3.2 Cell culture conditions .....   | 70 |
| 3.3 RHPA .....  | 71 |
| 3.4 Plate RIA .....   | 71 |

|   |    |
|---|----|
|   | xi |
| 3.5 Quantitative analysis .....   | 72 |
| 4. RESULTS .....  | 73 |
| 4.1 The effect of CRH on ir $\beta$ EP secretion from TM3<br>cells .....              | 73 |
| 4.2 The effect of CRH on ir $\beta$ EP secretion from<br>AtT20 cells .....            | 74 |
| 5. DISCUSSION .....   | 80 |
|   |    |
| V. LOCALIZATION OF CRH mRNA IN THE TESTIS BY <i>IN SITU</i><br>HYBRIDIZATION<br>..... | 83 |
| 1. ABSTRACT .....   | 84 |
| 2. INTRODUCTION .....   | 86 |
| 3. MATERIALS AND METHODS .....  | 87 |
| 3.1 Tissue preparation .....  | 87 |
| 3.2 Digoxigenin-labelled riboprobe synthesis .....                                    | 87 |
| 3.3 In-situ hybridization .....   | 88 |
| 3.4 Detection .....   | 89 |
| 4. RESULTS .....  | 91 |
| 4.1 CRH mRNA in the testis .....  | 91 |
| 4.2 Competition experiments and positive control .....                                | 91 |
| 5. DISCUSSION .....   | 99 |

|   |            |
|---|------------|
| <b>VI. GENERAL DISCUSSION</b> .....   | <b>102</b> |
| <b>A. CRH effect on ir<math>\beta</math>EP secretion from Leydig cells of adult rat</b>         |            |
| <i>testis in vitro</i> .....  | <b>102</b> |
| <b>B. CRH effect on ir<math>\beta</math>EP secretion in the rat testis <i>in vivo</i></b> ..... | <b>104</b> |
| <b>C. Pituitary-like POMC mRNA in the rat testis</b> .....                                      | <b>105</b> |
| <b>D. Temperature effect on the action of CRH</b> .....   | <b>106</b> |
| <b>E. Localization of CRH mRNA in the rat testis</b> .....                                      | <b>107</b> |
| <b>VII. APPENDIX</b> .....  | <b>110</b> |
| <b>CRH GENE</b> .....   | <b>110</b> |
| <b>POMC GENE</b> .....  | <b>111</b> |
| <b>RHPA</b> .....   | <b>112</b> |
| <b>VIII. BIBLIOGRAPHY</b> .....   | <b>113</b> |

**LIST OF TABLES**

1. Effects of CRH and  $\alpha$ -helical CRH-(9-41) on the percentage of total plaque-forming cells ..... 34

## **LIST OF FIGURES**

|     |   |    |
|-----|---|----|
| 1.  | The rate of plaque formation by ir $\beta$ EP-producing cells in the presence or absence of CRH . . . . .               | 23 |
| 2.  | The rate of change in ir $\beta$ EP plaque size in the presence or absence of CRH ( $10^{-7}$ M). . . . .               | 25 |
| 3.  | Ir $\beta$ EP plaque-forming cells immunostained with Leydig cell-specific monoclonal antibodies. . . . .               | 28 |
| 4.  | Dose-response curve of CRH effects on mean plaque size . . . . .  | 30 |
| 5.  | Dose-response curve of CRH effects on the percentage of plaque-forming Leydig cells. . . . .                            | 32 |
| 6.  | Parallel analyses of serial dilutions of TIF. . . . .   | 52 |
| 7.  | Effect of CRH and its antagonists on ir $\beta$ EP levels in TIF of pubertal rat . . . . .                              | 54 |
| 8.  | Effect of CRH and its antagonists on ir $\beta$ EP levels in TIF of adult rat. . . . .                                  | 56 |
| 9.  | Analysis of the RT/PCR products. . . . .  | 59 |
| 10. | Dose-response curve of CRH effects on mean plaque size and the percentage of plaque-forming cells in TM3. . . . .       | 75 |
| 11. | Dose-response curve of CRH effects on ir $\beta$ EP release from AtT20 cells. . . . .                                   | 77 |
| 12. | <i>In situ</i> hybridization staining of CRH mRNA in an adult rat testis using digoxigenin-labelled riboprobe . . . . . | 92 |
| 13. | <i>In situ</i> hybridization staining of CRH mRNA in testis and olfactory bulb . . . . .                                | 95 |

## **I. GENERAL INTRODUCTION**

### **A. Paracrine regulation in the testis**

Although the testis is primarily under the control of pituitary gonadotropins, there is increasing evidence that locally produced peptide hormones play important modulatory roles in the testis' response to the pituitary gonadotropins action on steroidogenesis and spermatogenesis. Sharpe (Sharpe, 1984) suggested that 1) the structural organization of the testis and 2) the organization and hormonal control of spermatogenesis are two factors that necessitate local control. The Sertoli, germ and interstitial cells each exert different effects on the other cell types, and these effects change according to the stage of the spermatogenic cycle. For example, seminiferous tubules located adjacent to Leydig cells modulate the morphology and function of these cells according to the stages of spermatogenic cycle in the tubules (Bergh, 1982; Syed et al., 1985a). In addition, co-culturing of isolated seminiferous tubules and Leydig cells affects Leydig cell testosterone secretion. Moreover, when depletion of germ cells occurs after experimental cryptorchidectomy (transplantation of a previously descended testis from scrotal sac to the abdominal cavity), Sertoli cell proteins such as androgen binding protein (ABP) and inhibin are drastically reduced (Jegou et al., 1983; Sharpe et al., 1986). When germ cells are selectively depleted (by X-irradiation), secretion of plasminogen activator protein from the Sertoli cells is inhibited.

Many peptide hormones, possibly of local origin, have demonstrated actions on steroidogenesis within the testis (Sharpe et al., 1987). For example, testicular inhibin (Bardin et al., 1990; Franchimont et al., 1989), luteinizing hormone-releasing hormone (LHRH) (Sharpe et al., 1981, 1983b), oxytocin, and vasopressin (Adashi et al., 1984) stimulate testosterone production, while CRH inhibited gonadotropin-stimulated testosterone production (Ulisse et al., 1989). In addition, local growth factors such as seminiferous growth factor (SGF), and insulin-like growth factor I (IGF-I) increase the rate of cellular proliferation and differentiation, and affect steroidogenesis (Bellve et al., 1989).

The evidence for local synthesis of regulatory peptides in the testis has come from a variety of studies that identify either the specific proteins, their corresponding mRNAs, or both. For example, the mRNAs encoding inhibin (Bardin et al., 1990), CRH (Thompson et al., 1987), oxytocin (Ivell et al., 1990), and POMC peptides (Chen et al., 1984; Pintar et al., 1984), is detected in testis, and peptide immunoreactivity is detected in cultured testicular cells (Fabbri et al., 1988, 1990; Morris et al., 1988). Moreover, the expression of a number of these peptides is regulated by the seminiferous tubules and/or other peptide hormones. For example, the expression of inhibin (Bhasin et al., 1989) and POMC peptides (Gizang-Ginsberg et al., 1985) in the testis depends on the stage of the seminiferous tubules. In addition, immunoreactive concentrations of CRH and  $\beta$ EP in testicular extracts or testicular interstitial fluid (TIF) are several fold higher than concentrations of these peptides in plasma and hypophysectomy does not completely abolish the

immunoreactivity of CRH and POMC-related peptides in the testis (Valenca et al., 1986; Yoon et al., 1988). These data suggest local paracrine and/or autocrine roles for these peptides. The site(s) of synthesis and action in the testis for the majority of the peptides mentioned above are not yet fully defined.

In the testis, POMC biosynthesis appears to occur in at least three distinct cell types. Leydig cells (Pintar et al., 1984), immature spermatocytes, and spermatogonia (Cheng et al., 1985). Immunoreactive CRH-like material (irCRH) has been shown in the testis, and specifically in Leydig and germ cells (Yoon et al., 1988; Audhya et al., 1989). Fabbri *et al.* (1990) demonstrated irCRH in media from Percoll-purified Leydig cell cultures, suggesting that these cells are capable of synthesizing CRH. It is not yet clear if Leydig cells are the primary source of CRH, or if other cells of the testis may be synthesizing the peptide.

Recently investigators examined the action of some of the local testicular factors on end-points other than steroidogenesis in Leydig cells. For example, Valenca demonstrated an acute stimulation of ir $\beta$ EP and immunoreactive adrenocorticotropin (irACTH) concentrations in TIF by the hypothalamic LHRH (Valenca et al., 1986). There is evidence that Sertoli cells in the rat produce an LHRH-like peptide (Sharpe et al., 1981, 1987).

## **B. Brief background on POMC and CRH**

The pituitary gland is the major site of synthesis of POMC (Antoni, 1986; Lundblad et al., 1988), the precursor of several different endocrine hormones such as

adrenocorticotropin (ACTH), the opioid  $\beta$ EP and melanocyte-stimulating hormone (MSH) (Eipper et al., 1980). The hypothalamic peptide CRH is the principal stimulator of POMC peptide secretion from the pituitary in response to stress (De Souza et al., 1985; Lundblad et al., 1988; Dunn et al., 1989). CRH regulates pituitary POMC peptide release via an interaction with a specific cell membrane receptor on pituitary corticotrophs (Wynn et al., 1983).

CRH messenger RNA (CRH mRNA) (diagram of the CRH gene is shown in Appendix I) is found in a wide variety of extrahypothalamic tissues including olfactory bulb (Imaki et al., 1989), pituitary, brain, spinal cord, adrenal, testis (Thompson et al., 1987), and placenta (Grino et al., 1987). POMC mRNA is also found in many tissues including adrenal, thymus and testis (Lacaze-Masmonteil et al., 1987) suggesting that these tissues have the capacity to synthesize CRH and POMC. In addition, CRH and POMC peptide hormones are detected in the placenta (Margioris et al., 1988) and adrenal (Evans et al., 1983), and CRH can stimulate POMC peptide secretion from the placenta (Petraglia et al., 1987a; Margioris et al., 1988). Also, CRH binding sites have been demonstrated in testis, spleen, liver, kidney and adrenal (Jitendra et al., 1985; Webster et al., 1988). Hence, it may be that many tissues have local (paracrine or autocrine) CRH/POMC interaction that are similar to that in the hypothalamic/pituitary axis.

### C. POMC messenger ribonucleic acid (mRNA) in the testis

In the early 1980s, Pintar *et al.* (1984) and Chen *et al.* (1984) characterized the

POMC mRNA (diagram for the POMC gene is found in appendix II) (Jeannotte et al., 1987) in the adult rat testis by Northern blot analysis. Pintar and coworkers (1984) and Gizang-Ginzberg and coworkers (1985) localized the POMC mRNA in rat and mouse Leydig cells using the *in situ* hybridization method. This POMC mRNA was at least 200nt shorter than the POMC mRNA of 1100nt in the pituitary. The testicular POMC mRNA has most of Exon3, which contains most of the protein coding sequence, but is missing Exons 1 and 2, and therefore lacks the codons for amino terminal signal peptide (Jeannotte et al., 1987). This POMC mRNA is approximately 100 times less abundant than the POMC mRNA in the pituitary (reviewed in Bardin et al., 1987). Other nonpituitary tissues also contain this short POMC mRNA, such as duodenum, kidney, colon, liver, and spleen (DeBold et al., 1988).

In pituitary corticotrophs, the regulated POMC is packaged into secretory vesicles and undergoes cleavage before the POMC-derived products are secreted (Glembotski, 1981; Gumbiner et al., 1981, 1982; Tooze et al., 1986, 1987). Recently, Clark *et al.* (Clark et al., 1990), in their transfection studies on GH<sub>3</sub> cells, demonstrated that cells containing the full-length POMC transcript were able to secrete  $\beta$ EP and ACTH hormone (another POMC-derived peptide). Cells transfected with an expression vector for the short transcript were unable to secrete any of these peptides. These data suggest that the pituitary-like POMC message may be necessary in successful packaging and secretion of the POMC-derived peptides.

The lack of detectable signal-peptide coding sequences in the POMC-like RNA in

tissues such as the testis raised questions about the source and fate of POMC peptides in this tissue. Are POMC peptides synthesized from the short transcript and therefore, because they lack the signal peptide, not secreted or constitutively secreted? Or, is there regulated secretion of POMC peptides made from a low abundance, full-length POMC mRNA that encodes POMC prohormones that is precursor to regulated secretory products? Finding answers to these questions formed part of the basis for the studies outlined in this dissertation.

During the course of our research, Lacaze-Masmonteil and coworkers (1987), using S<sub>1</sub> nuclease assay (a sensitive method to detect low abundant mRNA), were able to identify, in the human testis, a long POMC mRNA similar in length to the pituitary POMC mRNA, but in levels approximately 100 times less than the short transcripts in the adult human testis.

#### D. POMC-derived peptide and CRH function in the testis

Biochemical and physiological responses to several POMC peptides have been documented to occur in the testis (; Orth et al., 1986; Boitaini et al., 1986; Bardin et al., 1987; Knotts et al., 1988). Opiate receptors are found on Sertoli cells in culture (Fabbri et al., 1985) and  $\beta$ EP inhibits follicle-stimulating hormone (FSH)-stimulated androgen binding protein (ABP) production from these cells. Intratesticular injection of the opiate antagonists nalmefene or naloxone increased the compensatory hypertrophy following unilateral castration (Bardin et al., 1987; Cicero et al., 1989). The antagonists also increased rat androgen binding protein suggesting that  $\beta$ EP

and/or other opioids (enkephalins and dynorphins which are also localized in the testis) (Kilpatrick et al., 1986; Douglas et al., 1987; Garrett et al., 1989) inhibit Sertoli cell growth and secretion during early testicular development.  $\beta$ EP acutely stimulated testosterone secretion in Leydig cell cultures prepared from 20-day-old rats (Bardin et al., 1987). In contrast, perfusion of  $\beta$ EP or naloxone in intact adult rat testes *in vitro* or *in vivo* had no effect on testosterone levels while ACTH increased testosterone secretion (Sharpe et al., 1987; Juniewicz et al., 1988).  $\alpha$ -MSH, another POMC peptide, stimulates the production of ABP and Sertoli cell number (Boitaini et al., 1986; Orth, 1986). ABP and Sertoli cells are essential for normal spermatogenesis.

From these studies has come the suggestion that POMC peptides which are synthesized in the testis may have paracrine and/or autocrine functions in the male gonads. Implicit in this suggestion is the assumption that POMC peptides are actively secreted in a regulated fashion from the testicular cells in which they are made. Recently, Fabbri *et al.* (1988) demonstrated gonadotropin stimulation of *ir* $\beta$ EP secretion from cultures of fetal Leydig cells; in addition, Valenca and coworkers showed LHRH and LH stimulation of *ir* $\beta$ EP secretion from the whole adult rat testis (Valenca et al., 1986). It was also shown that CRH inhibited luteinizing hormone(LH)-stimulated testosterone secretion from Leydig cells in culture (Ulisse et al., 1989). From these results, Fabbri, in his review article on opioids (Fabbri, 1990), suggested an antireproductive role for  $\beta$ EP and CRH in the testis, in addition to their known antireproductive functions in the brain and the hypothalamus

(Rivier,C et al., 1984, 1986; Petraglia et al., 1987b; Barbarino et al., 1989a,b; Fabbri et al., 1989).

#### **E. Developmental regulation in the testis**

Testosterone production and spermatogenesis are essential for normal male reproduction. Their onset are the markers for puberty. Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) are the major regulators of these markers. In prepubertal animals, LH and FSH, which are in low circulating levels, do not affect testicular maturation (Purvis et al., 1979; Pilsworth et al., 1981; Ritzen et al., 1981; Russel et al., 1987). At puberty, the hypothalamic LHRH stimulates the secretion of LH and FSH from gonadotrophs in the pituitary and in turn, these peptides, in high circulating levels, stimulate testosterone production and spermatogenesis. In addition, the maturation process involves changes in expression of genes for a variety of secretory peptides, few of which are under gonadotropin control. For example, inhibin and POMC expression is highest at puberty (Shaha et al., 1984; Chen et al., 1987; Rivier,C et al., 1988; Yoon et al., 1988; Keeping et al., 1990), and are stimulated by LH or FSH. In the mouse, ir $\beta$ EP staining in interstitial cells progressively increases throughout fetal life; at the time of birth, the percentage of ir $\beta$ EP stained cells was found to be 55% of interstitial cells. The number declines after birth to 12% at 5 days of age, increases to almost 100% by 40 days and after. Ir $\beta$ EP and irACTH declines after hypophysectomy and increases after human chorionotropic hormone (hCG) treatment. In the rat, Yoon *et al.* (1988)

demonstrated that irCRH level was high at 10 days of age, decreased sharply at 20 days, and rebounded at 60 and 90 days. Hypophysectomy decreased irCRH levels in the testis. In addition, changes in LH, FSH and vasopressin receptor number and steroidogenesis during development have been observed (Huhtaniemi et al., 1981, 1982; Chase et al., 1983; Tahri-Joutei et al., 1989b). These changes in the expression or action of local peptides at different ages of the animal led us to investigate whether the action of CRH in the testis is developmentally regulated.

#### **F. Temperature changes and cryptorchidism**

The testes of many mammalian species reside in the scrotum, which serves a thermoregulatory function and maintains an optimum environment for spermatogenesis. The normal scrotal temperature is about 32-34°C which is several degrees cooler than the core body temperature of 37°C. Evidence suggested that the cooler environment of the scrotum seems to be essential for maintenance of normal testicular structure and function in the adult animal. For example, profound tubular damage (Chowdhury et al., 1964, 1970; Davis et al., 1966), and morphological and functional changes in Sertoli and Leydig cells have been extensively documented in artificial cryptorchidism (Risbridger et al., 1981; Jegou et al., 1983; Huhtaniemi et al., 1984; Lunstra et al., 1988; Sirvent et al., 1989). Decrease in testicular weight was observed as well as hyperresponsive testosterone response to hCG stimulation in vitro (Iturriza et al., 1979), decrease in arginine vasopressin (AVP) (Tahri-Joutei et al., 1989a), LH, prolactin (PRL) and FSH receptors occurred in the adult rat (Risbridger

et al., 1981; Huhtaniemi et al., 1984; Bergh et al., 1987) as well as decrease in DNA synthesis and alteration in several steroidogenic enzymes' activities (Damber et al., 1983; Fujisawa et al., 1988; Hotta et al., 1988; Nakamura et al., 1988). Given the sensitivity of the organ to small temperature changes, one wonders how such changes influence cell-cell interaction through the expression and the action of local paracrine regulators. Intratesticular irCRH has been shown to decrease when rat testis was moved to the abdomen (Yoon et al., 1988). This is not surprising since irCRH is detected in germ cells of the tubules and germ cells are very vulnerable to temperature changes.

It has also been reported that levels of ir $\beta$ EP and irACTH in the blood are elevated during hyperthermia or hypothermia (Nakane et al., 1985; Vescovi et al., 1990). It is not known if these increases are at the brain or pituitary levels. These documentations lead us to investigate the role of small temperature changes, as a stress stimulus, on the action of CRH on POMC peptides.

### **G. Specific aims**

1) to look at the effect of CRH on ir $\beta$ EP secretion from Leydig cells *in vitro*. The reverse hemolytic plaque assay (RHPA) will be used to detect ir $\beta$ EP secretion from individual cells. Leydig cells will be identified by immunocytochemistry using specific monoclonal antibodies to Leydig cell surface antigens.

2) to assess the physiological role of CRH on testicular  $\beta$ EP in the whole animal. This study will help determine whether CRH is a local regulator in the testis. Since the stages of spermatogenesis seem to have influence on the behavior of testicular cells, pubertal and adult animals will be used to determine whether the action of CRH is modulated by the testicular microenvironment.

3) to establish whether the rat testis has a full length pituitary-like POMC mRNA capable of synthesizing a POMC protein whose secretion is regulated.

4) to study the effect of temperature on the CRH/POMC system since it is known that spermatogenesis, and to a lesser degree, steroidogenesis are sensitive to small temperature changes. In addition, CRH/POMC system is known to be responsive to stress stimuli.

5) to localize the site(s) of CRH synthesis in the testis.

**II. STIMULATION OF IR $\beta$ -ENDORPHIN SECRETION BY  
CORTICOTROPIN-RELEASING HORMONE IN PRIMARY RAT  
LEYDIG CELL CULTURES\*.**

**N. L. Eskeland, D. I. Lugo, J. Pintar and B. S. Schachter**

**Departments of Pharmacology (N.L.E.), Obstetrics, Gynecology, and Reproductive  
Science, and Anatomy (B.S.S.), Mount Sinai Medical School, New York, N.Y.  
10029, and Department of Anatomy (D.L.L., J.P.), Columbia University College of  
Physicians and Surgeons, New York, N.Y. 10032**

**Address all correspondence and requests for reprints to: Dr. Beth Schachter,  
Department of Obstetrics Gynecology, and Reproductive Science, Box 1175, Mt.  
Sinai Medical School, New York, N.Y. 10029**

**\*Portions of these studies were presented at the 70th Annual Meeting of The  
Endocrine Society , June 8-11, 1988, New Orleans, LA. This work was supported  
by NIH grant HD18110 and an Irma T. Hirschl Foundation Fellowship to B.S.S.  
and NIH grant HD18592 to J.P.**

**Runnig Title: CRH Effect on  $\beta$ EP from Leydig Cells**

**Endocrinology 124:2914 (1989)**

## 1. ABSTRACT

CRH, a hypothalamic peptide, is a potent stimulator of POMC synthesis and secretion in corticotropic cells of the pituitary. POMC peptides have also been localized in other cells such as testicular Leydig cells. Drawing on these observations, a reverse hemolytic plaque assay and immunocytochemistry were used to study the effect of CRH on secretion of the POMC peptide,  $\beta$ EP, from normal rat primary Leydig cell cultures. Our results showed that in enriched Leydig cell preparation treated with  $\beta$ EP antiserum (diluted 1:50) and complement (diluted 1:25), approximately 18% of the Leydig cells formed plaques. The addition of an increasing concentration of CRH (from  $10^{-11}$ M to  $10^{-7}$ M) increased the percentage of plaques by 83% and the average size of the plaque by 86%. When the CRH antagonist, CRH9-41 ( $10^{-6}$ M) was added in the presence of CRH, the increase in plaque number and average size was abolished. Preabsorption of the antiserum with  $\beta$ EP ( $2 \mu\text{g}/\mu\text{l}$  of antiserum) overnight at  $4^{\circ}\text{C}$  abolished the formation of plaques. These results demonstrate that the Leydig cells have CRH receptors and that  $\beta$ EP secretion from these cells is stimulated by CRH.

## 2. INTRODUCTION

The pituitary gland is the major site of synthesis of POMC, the precursor of several different endocrine hormones. The hypothalamic peptide CRH is the principal stimulator of POMC peptide secretion from the pituitary. CRH regulates pituitary POMC peptide release via an interaction with a specific cell membrane receptor on pituitary corticotrophs (Lundblad et al., 1988).

Small quantities of POMC are produced in a wide variety of tissues throughout the body, including the testis, ovary, placenta (Bardin et al., 1987), and adrenal (Evans et al., 1983). In some organs more than one cell type may synthesize POMC. For example in the testis, the prohormone is made in both Leydig cells and immature spermatocytes (Chen et al., 1984; Pintar et al., 1984; Cheng et al., 1985; Gizang-Ginsberg et al., 1985).

Recent studies have shown that immunoreactive CRH (Yoon et al., 1988) and CRH mRNA (Thompson et al., 1987) are present in the testis, suggesting that some cells in this tissue have the capacity to synthesize CRH. The peptide is also detected in placental perfusates (Margioris et al., 1988), and in this tissue it can stimulate POMC peptide secretion (Petraglia et al., 1987b; Margioris et al., 1988). CRH-binding sites have also been demonstrated in testis, spleen, liver, kidney, and adrenal (Jitendra et al., 1985; Webster et al., 1988). Hence, it may be that many tissues have local CRH/POMC stimulus/ response systems which, at least qualitatively, resemble that

in the hypothalamic/pituitary axis.

The current study was designed to test the effect of CRH on the release of the POMC-derived peptide  $\beta$ EP from testicular Leydig cells. We chose to use the RHPA in our studies instead of RIA because RIA does not discriminate between  $\beta$ EP-secreting and nonsecreting cells. Moreover, the RHPA, but not the RIA, allows for subsequent immunocharacterization of the specific cells that secrete  $\beta$ EP. Finally, other workers have reported a lack of success in detecting secreted  $\beta$ EP in adult Leydig cell cultures by RIA, possibly due to a high level of secreted proteases in their cultures (Fabbri et al., 1988) (Bardin, W., personal communication).

The data in the current study provide the first direct evidence that Leydig cells of the adult rat actively secrete ir $\beta$ EP and that this action is specifically stimulated by CRH. Hence, the results demonstrate that Leydig cells have functional CRH receptors, and that CRH may have a paracrine or autocrine function in the testis.

### 3. MATERIALS AND METHODS

#### 3.1 *Chemicals*

CRH,  $\alpha$ -helical CRH-(9-41) (a CRH competitive antagonist), and human  $\beta$ EP were obtained from Peninsula Laboratories (Belmont, CA); guinea pig complement, penicillin-streptomycin, sterile saline, HEPES-buffered solution and Dulbecco's Modified Eagle's Medium (DMEM) were obtained from Gibco (Grand Island, NY); Staphylococcal protein-A, poly-l-lysine, BSA, chromium chloride hexahydrate, paraformaldehyde were from purchased from Sigma (St. Louis, MO); sheep blood preserved in modified Alsever's solution was obtained from Rockland (Gilbertsville, PA); collagenase was obtained from Millipore Corp. (Freehold, NJ); and Percoll was from Pharmacia (Uppsala, Sweden). Reagents for avidin-biotin peroxidase immunocytochemistry were obtained from Vector Laboratories (Burlingame, CA), and 3,3'-diaminobenzidinetetrahydrochloride was obtained from Aldrich Chemical Co., Inc. (Milwaukee, WI).

#### 3.2 *Antisera*

The  $\beta$ EP antiserum (EP-3) was the generous gift of A. Liotta (NIH).

This antiserum, which was raised against synthetic porcine  $\beta$ EP, has been extensively characterized (Liotta et al., 1981); in particular, it cross reacts on an equimolar basis

with camel  $\beta$ EP, camel  $\beta$ EP-(1-27), the human forms of these peptides, their  $\alpha$ -N-acetyl derivatives, and the common precursor molecules. It does not react with  $\alpha$ - or  $\gamma$ -EP.

The Leydig cell specific monoclonal antisera LC-1C6 and LC-6H6 were gifts of E.M. Eddy (Research Triangle Park, NC). In enzyme-linked immunosorbent assays on isolated testicular cells and in immunocytochemical studies on fixed testis sections, these antisera reacted only with Leydig cells (Hedger et al., 1986). Approximately 60-70% of the isolated cells stained with the monoclonal antibodies compared to 83.1% that gave positive staining for  $3\beta$ -hydroxysteroid dehydrogenase (Hedger et al., 1986, 1987). In our Leydig cell preparations a similar percentage of cells stained with the monoclonal antisera, as described below.

### *3.3 Animals, cell dispersion, and purification*

Adult male Sprague-Dawley rats (275-300 gm) were obtained from Charles River Laboratories (Wilmington, MA). Rats were housed under standard laboratory conditions, with free access to food and water. Animals were killed by CO<sub>2</sub> asphyxiation. Rat testes were perfused through the testicular artery with saline, using a 28.5 gauge needle, to remove most of the red blood cells. The testes were decapsulated and enzymatically dispersed with collagenase, and Leydig cells were purified by the method of Anakwe et al. (Anakwe et al., 1985) with few modifications. For each assay, four testes were placed in a 50-ml conical tube with 6 ml collagenase solution (1.2 mg/ml collagenase in DMEM-0.1% BSA containing 25

mM HEPES solution, 10 units penicillin and 10  $\mu$ g streptomycin) and incubated for 20 min at 34°C in a shaking water bath at 80 cycles/min. The cell suspension was diluted with 4 vol DMEM-0.1% BSA solution and kept at room temperature for 2 min to allow the seminiferous tubules to settle. The supernatant was decanted through 4 layers of gauze into a fresh 50 ml tube. The tubules were washed once with DMEM-0.1% BSA solution, and the resulting supernatant collected. The combined supernatants were centrifuged twice at 118 x g for 5 min, and the pellet containing the interstitial cells was further purified using Percoll density gradient centrifugation. Briefly, 20mls of an isotonic 80% Percoll solution were layered under 20 ml of an isotonic 40% Percoll solution in a 50-ml conical tube. Interstitial cells were layered on top of the gradient in 3 ml DMEM-0.1% BSA solution and centrifuged for 20 min at 500 x g. The Leydig cell fraction formed a discrete band at the interface of the two Percoll fractions. At least 60% of the cells in this band stained with the monoclonal antibodies LC-1C6 and LC-6H6 to Leydig cell surface antigens (Hedger et al., 1986). Viability of the cells was more than 90% by trypan blue exclusion. This fraction was collected by aspiration and diluted with 3 vol DMEM-0.1% BSA solution, and the cells were collected by centrifugation, washed twice with DMEM-0.1% BSA solution, and suspended in the solution for the assay.

### 3.4 RHPA

The RHPA was performed as described by Smith and coworkers (Smith et al., 1986) (see diagram in appendix III). Two chambers per slide were constructed. The

cell mixture containing equal volumes of enriched rat Leydig cell preparations (approximately  $2 \times 10^5$  cells/ml) and an 18% (vol/vol) suspension of protein-A-coated ovine erythrocytes was infused into each chamber and incubated in a humidified CO<sub>2</sub> incubator for 45 min. Unattached cells were removed by infusing DMEM-0.1% BSA solution. The antiserum  $\beta$ EP (diluted 1:50) and the hormone CRH in DMEM-0.1% BSA solution were added, and slides were incubated at 37 C for the indicated length of time. Then, complement (diluted 1:25) was added, and the slides were further incubated for 1 h. The reaction was stopped by immersing the slides in 2% paraformaldehyde in phosphate buffered saline (PBS). The fixation continued overnight, then slides were rinsed, stained with toluidine blue or cresyl violet, and stored in 0.1 M phosphate buffer at 4°C.

### *3.5 Immunocytochemistry*

In some experiments the slides from the RHPA were processed for avidin-biotin-peroxidase immunocytochemistry. Briefly, coverslips were removed, and slides air dried, then dessicated for 30 min to insure that cells remained attached. Slides were then soaked in 0.15 M PBS and incubated in 1) diluted normal goat serum for 20 min to block nonspecific binding; 2) primary antiserum (mixture of LC-1C6 and LC-6H6, each at a 1:20 dilution) overnight at 4 C, followed by washing; 3) biotinylated goat anti-mouse IgM (diluted 1:222) for 45 min and washed; and 4) avidin DH and biotin-conjugated peroxidase H for 45 min and washed. The reaction product was developed in freshly prepared DAB and 0.003% hydrogen peroxide in

0.04 M phosphate buffer for 5 min. After thorough rinsing, the slides were counterstained as described above, dehydrated and coverslipped.

For negative controls, primary antiserum was either omitted or replaced by normal mouse ascites fluid. In addition, an enriched Leydig cell preparation was divided in half, and one half was exposed to  $\beta$ EP antiserum for 2 h before immunocytochemistry, while the other was tested with the monoclonal antibodies directly. No difference in the percentage of cells staining with the monoclonal antibodies was observed in the two samples, verifying that the  $\beta$ EP antiserum did not interfere with immunocytochemical detection of Leydig cells. Immunocytochemistry caused some random loss of red blood cells from the chambers, but did not change the measured plaque areas. Moreover, while ghost cells were visible around plaques before immunocytochemistry, most were lost after this procedure.

### *3.6 Quantitative analysis*

The analysis was done using Axiomat Image Analyzer System, and the plaque areas were calculated using the Drexel analysis program (Feingold et al., 1986). In all experiments, chambers without antagonist were tested in duplicate, while each condition with antagonist was tested in a single chamber. Areas of 30-60 plaques were measured for each test and then averaged. The percentage of cells with plaques was determined after screening at least 150 cells/condition. Minimum plaque diameter corresponded to 2 red blood cell diameters. Analysis of variance was used to determine overall differences among the different experimental

conditions.


## 4. RESULTS

### 4.1 The rate of plaque formation on ir $\beta$ EP-producing cells in the presence or absence of CRH


In preliminary studies secretion of ir $\beta$ EP from Percoll gradient-enriched Leydig cell preparations was examined in the presence or absence of CRH (Figs. 1 and 2). Samples were incubated with  $\beta$ EP antiserum with or without CRH for varying times, then complement was added. As seen in Figure 1, samples cultured in the absence of CRH showed a time-dependent increase in the percentage of plaque-forming cells, reaching about 17% at 4 h. Samples incubated with  $10^{-7}$  M CRH showed an increase in the rate of plaque formation, reaching an apparent plateau (also of  $\sim 17\%$  of the cells) at 2 h. As seen in Figure 2, the mean plaque area continued to increase during the 4-h period, and the mean plaque size at all time points was greater in the presence than in the absence of CRH. No plaques were seen in chambers lacking  $\beta$ EP antisera or complement or in samples tested with antiserum preincubated overnight at 4 C with  $2 \mu\text{g}$  synthetic human  $\beta$ EP/ $\mu\text{l}$  antiserum. These results show that  $\beta$ EP secretion from individual cells could be readily detected by this assay, and that the cells remain viable and capable of  $\beta$ EP secretion for several hours. Importantly, these results suggest that  $\beta$ EP secretion is stimulated by CRH. Therefore, a more thorough analysis of the effect of CRH was conducted.

### 4.2 Monoclonal antibodies specific to Leydig cell surface antigens

**Figure 1.** The rate of plaque formation by ir $\beta$ EP-producing cells in the presence or absence of CRH. The analysis was made by counting at least 200 cells/chamber in duplicate chambers for each timepoint. Values shown are the mean  $\pm$  SD.



**Figure 2.** The rate of change in ir $\beta$ EP plaque size in the presence or absence of CRH ( $10^{-7}$  M). The values are the mean  $\pm$  SE of determinations made from 25-30 plaques in a chamber.




To restrict our investigation to Leydig cells, in some assays we assessed only those cells that could be stained by a combination of Leydig cell-specific monoclonal antisera. Therefore, after the RHPA, cells were analyzed immunocytochemically as described in Material and Methods section. Approximately 60% of the cells stained with the monoclonal antibodies. Of the unstained cells (40%), only 4.5% had plaques in the presence of CRH at  $10^{-7}$  M. Examples of cells that formed plaques due to  $ir\beta EP$  secretion and were subsequently stained with Leydig cell antibodies are shown in Figure 3. Figure 3A shows a small plaque formed around a Leydig cell cultured in the absence of CRH; Figure 3B shows a larger plaque formed around a cell maintained in the presence of  $10^{-8}$ M CRH.


#### 4.3 CRH dose-response curves in the presence or absence of CRH-(9-41)

A complete CRH dose response curve was then obtained on samples incubated for 2 h. In addition, a parallel analysis was carried out in the presence of the CRH antagonist  $\alpha$ -helical CRH-(9-41)( $10^{-6}$  M). Figure 4 shows that a significant CRH concentration-dependent increase in mean plaque area occurs surrounding immunostained Leydig cells ( $p < 0.05$ ), reaching an approximately 85% increase in the presence of  $10^{-8}$ M CRH or more. In contrast, cells cultured in the presence of the antagonist showed no CRH-related increase in mean plaque size, suggesting that CRH stimulates  $ir\beta EP$  through a classical membrane receptor dependent mechanism. In addition, it should be noted that small plaques were detected in the absence of added CRH, and there was no further reduction in the mean area of these plaques

**Figure 3.** IrβEP plaque-forming cells immunostained with Leydig cell-specific monoclonal antibodies. **A**, a cell tested under basal conditions; **B**, a cell tested after stimulation with  $10^{-8}$  M CRH. Magnification, x320.




A



B

**Figure 4.** Dose-response curve of CRH effects on mean plaque size, which is an index of the amount of ir $\beta$ EP secreted from a Leydig cell. The RHPA was performed for 2 h. The mean size of the plaques in the antagonist [CRH-(9-41)] treated cultures remains at basal levels. Values in the top curve represent the mean  $\pm$  SE of determinations made from 40-60 plaques in duplicate chambers. Values in the lower curve (+ antagonist) represent the mean  $\pm$  SE of determinations made from 20-35 plaques in a chamber. The responses to CRH and the CRH antagonist in this experiment are representative of at least three separate RHPAs.



**Figure 5. Dose-response curve of CRH effects on the percentage of plaque-forming Leydig cells. Values in the top curve represent the average of two determinations made from at least 150 cells/chamber in duplicates. Values in the lower curve (+ antagonist) represent the percentage of plaque-forming cells in a chamber. The responses to CRH and the CRH antagonist in this experiment are representative of at least three separate RHPAs.**




TABLE 1

Effects of CRH and  $\alpha$ -helical CRH-(9-41) on the percentage of total-forming cells

| Treatment groups   | Antagonist [ $\alpha$ -helical CRH-(9-41)] |                    |
|--------------------|--|--------------------|
|                    | -  | +                  |
| Basal (no CRH)     | 12.8 $\pm$ 1.6 (5)                         | 12.0 $\pm$ 1.7 (3) |
| CRH ( $10^{-9}$ M) | 19.9 $\pm$ 2.0 (4) <sup>a</sup>            | 12.2 $\pm$ 1.9 (3) |
| CRH ( $10^{-7}$ M) | 20.1 $\pm$ 2.1 (4) <sup>a</sup>            | 12.9 $\pm$ 2.0 (3) |

Numbers in parentheses indicate the number of determinations. Values are the mean  $\pm$  SE. Two-way analysis of variance, followed by Student-Newman Keuls multiple comparison test, were performed. The level of significance chosen was  $p < 0.05$ .

<sup>a</sup> Values significantly different from basal levels without antagonist.

in the presence of the antagonist. Other results, in which immunostaining was not done, yielded results indistinguishable from those shown in Figure 4.

Figure 5 shows a separate analysis of the same experiment, in which the percentage of immunostained plaque-forming cells was plotted. There was a significant CRH concentration-dependent effect on the cells ( $p < 0.05$ ) by this criterion also. Here again we note that a substantial fraction ( $\sim 15\%$ ) of the Leydig cells formed plaques in the absence of CRH. In the presence of the secretagogue, only an additional 10-15% of the cells formed plaques.

Table 1 summarizes the results from several experiments. This analysis ignored the immunostaining, so that data from several experiments, with and without immunocytochemistry, could be analyzed together. The percentage of total plaque-forming cells in the presence or absence of CRH and the antagonist was calculated. Two-way analysis of variance showed a significant difference between the groups treated with CRH alone and all other groups ( $p = 0.006$ ). From these results, we can further confirm that CRH causes a significant increase in the number of plaque-forming cells after 2 h of treatment, and that the antagonist inhibits CRH's effect.

## 5. DISCUSSION

POMC-derived peptides have been identified in testes of several mammalian species (Tsong et al., 1982), and a POMC mRNA capable of encoding the secretory prohormone has been found in human (Lacaze-masmonteil et al., 1987). In addition, biochemical and physiological responses to several POMC peptides have been shown to occur in this organ (Fabbri et al., 1985; Orth, 1986; Bardin et al., 1987; Knotts et al., 1988). From these findings has come the suggestion that POMC peptides synthesized in testes may have paracrine and/or autocrine functions in the male gonads. Implicit in this suggestion is the assumption that POMC peptides are actively secreted in a regulated fashion from the testicular cells in which they are made. Recently Fabbri *et al.* (1988) elegantly demonstrated selective hormonal stimulation of ir $\beta$ EP secretion from cultures of fetal Leydig cells while Valenca and Negro-Vilar (1986) demonstrated regulated secretion of ir $\beta$ EP from the adult whole testes in vivo and in vitro. Attempts to identify secreted POMC-derived peptides from testicular cells in culture by classical RIA appear to have been thwarted by proteases possibly secreted principally from Sertoli cells in the cell preparations (Fabbri et al., 1988) (Bardin, W., personal communication).

We focused our analysis specifically on  $\beta$ EP, because its presence and putative functions in the testis have been the most extensively documented of the POMC peptides (Fabbri et al., 1985; Orth, 1986; Bardin et al., 1987; Knotts et al., 1988). Moreover, we restricted our analysis to Leydig cells, because this cell type contains

$\beta$ EP (Tsong et al., 1982; Bardin et al., 1987), while the germ cells, which also express the POMC gene, appear to cleave the protein to the shorter  $\alpha$  and  $\gamma$  forms of the molecule (Cheng et al., 1985; Lebouille et al., 1986). Little, if anything, is known about the physiological roles of these forms of EP.

The RHPA, used in conjunction with immunocytochemical identification of Leydig cells, allowed us not only to study stimulated secretion of ir $\beta$ EP, but also to assess whether there is heterogeneity among Leydig cells in their capacities to secrete the hormone and respond to a secretagogue. We chose CRH as the secretagogue to test because this peptide is a potent stimulator of POMC peptide secretion from the pituitary (Antoni, 1986), and recent studies have suggested that CRH may also be synthesized locally within the testis (Thompson et al., 1987; Yoon et al., 1988).

Our results have demonstrated that a subset (>10%) of Leydig cells secretes a low but reproducibly detectable amount of ir $\beta$ EP in the absence of the test secretagogue. CRH increases the rate of ir $\beta$ EP release from these cells, but, as indicated by result of the time-course study, it does not seem to recruit new cells into this population of secreting cells. As shown in Figure 2, CRH increases the amount of ir $\beta$ EP released per cell up to 4 h (the longest time point studied), indicating that the cells remained viable and capable of responding to CRH for several hours. Whether the CRH-dependent increase in plaque size over several hours reflects an effect of the hormone on de novo POMC biosynthesis as well as secretion remains to be determined. As shown in Figures 4 and 5, the effect of CRH on ir $\beta$ EP occurs in a dose-dependent fashion, with a half-maximal response at about 0.7 nM CRH, which

is similar to the dissociation constant of 0.76 nM for CRH in the anterior pituitary reported by Wynn *et al.* (1983). Moreover, CRH stimulated secretion is completely inhibited by the CRH antagonist, suggesting that CRH is working through a specific receptor. Hence, the Leydig cell response to CRH is similar to that produced by primary cultures of pituitary corticotrophs with respect to both the concentration of CRH giving a half maximal response and the ability of the  $\alpha$ -helical CRH-(9-41) antagonist to inhibit the stimulation (Rivier, J *et al.*, 1984). Whether the two cell types make use of identical intracellular mechanisms for CRH stimulated POMC peptide secretion remains to be determined.

The mechanisms underlying the observed heterogeneity of Leydig cell  $\text{ir}\beta\text{EP}$  production and CRH responsiveness are unknown. Heterogeneity in other biochemical markers of Leydig cells has been noted (Purvis *et al.*, 1979). An obvious morphological heterogeneity in the testis is that of the waves of spermatogenesis occurring within individual seminiferous tubules (Pilsworth *et al.*, 1981). Indeed, biochemical differences among Sertoli cells isolated from tubule segments containing sperm at different stages of differentiation have been noted (Ritzen *et al.*, 1981). Perhaps, quantitative or qualitative differences among paracrine signals released into the interstitium from tubular cells of these various stages cause the heterogeneity among the Leydig cells.

Local CRH/POMC interaction in other tissues have also recently been documented. For example, CRH gene expression and CRH-stimulated POMC peptide secretion has been shown to occur in the human placenta (Petraglia *et al.*, 1987b; Margioris *et*

al., 1988). If, similar to POMC gene, there is but a single CRH receptor gene per haploid genome in mammals, it may be hypothesized that the POMC gene and CRH receptor gene share common sequence elements that result in their coordinate expression in the same cells.

**III. CORTICOTROPIN-RELEASING HORMONE STIMULATION  
OF  $\beta$ -ENDORPHIN SECRETION IN THE RAT TESTIS *IN VIVO***

**N. L. Eskeland, C. Molineaux, C. A. Chaparro, B. S. Schachter**

**Departments of Pharmacology (N.L.E., C.M.), Obstetrics, Gynecology, and  
Reproductive Science, and Anatomy (B.S.S., A.C.), Mount Sinai Medical School,  
New York, N.Y.**

## 1. ABSTRACT

Corticotropin-releasing hormone (CRH) stimulates  $\beta$ -endorphin ( $\beta$ EP) secretion from adult rat Leydig cells *in vitro*. To evaluate the relevance of this action of CRH in a physiological context, we studied the effect of CRH on  $\beta$ EP secretion in the testis in whole animals.

In the current study, we measured the influence of locally infused CRH and synthetic analogs of it on  $\beta$ EP concentration in testicular interstitial fluid (TIF). In all animals, the contralateral testis was infused with the saline vehicle alone, and thus served as a control for the other, peptide-infused testis. Following a 2 h infusion of a 60  $\mu$ l volume, TIF was collected and assayed for  $\beta$ EP by RIA.

CRH (10 pmoles/min), CRH-(9-41) (10 or 25 pmoles/min), and the new CRH antagonist [DPhe<sup>12</sup>, Nle<sup>21,38</sup>, C $\alpha$ MeLeu<sup>37</sup>]<sub>r</sub>CRH(12-41) (CRH-(12-41) (10 pmoles/min) did not alter TIF volumes compared to those of control testes.

In the pubertal rat, CRH stimulated *ir* $\beta$ EP levels in TIF approximately 3-fold ( $p = 0.002$ ;  $n = 9$ , two tailed t-test, level of significance  $p < 0.05$ ). The antagonist  $\alpha$ -CRH-(12-41), infused along with CRH, resulted in TIF *ir* $\beta$ EP concentrations that were slightly but significantly lower than in paired saline controls ( $p = 0.03$ ,  $n = 7$ ). These results demonstrate that the intact testis of the pubertal rat is responsive to CRH. Moreover, they suggest that, at this developmental stage, endogenously produced CRH may have a submaximal stimulatory effect on local  $\beta$ EP release.

CRH-(9-41) which, *in vitro* acted purely as an antagonist, in the intact pubertal

animal, had a small (1.6-fold) but significant stimulatory effect on TIF ir $\beta$ EP concentrations ( $p = 0.04$ ,  $n = 7$ ). This difference in action suggests the importance of chemical and/or structural microenvironment on the direction of response to the peptide hormone analog.

In adult animals, all the test peptides were without effect. These results, in conjunction with data from other studies demonstrating that testicular CRH levels are much higher in the adult than in the prepubertal animal, suggest that CRH production in adult testis is high enough to desensitize, and perhaps, down-regulate local CRH receptors.

The data presented here, in conjunction with result of several other studies, demonstrate that  $\beta$ EP release from cells in the testis is a regulated process. Regulated secretion of the peptide implies that it is derived from a mRNA that contains a signal-peptide coding region. The readily detectable POMC-like RNAs in testis lack the 5' region found in the pituitary form of POMC mRNA, including the signal peptide coding sequence. Thus these short RNAs are not capable of encoding a precursor for peptides whose secretion is regulated. In the current study we document the presence of a low abundance mRNA that is indistinguishable from the pituitary form, and is therefore probably the source for POMC prohormone production in the testis.

## 2. INTRODUCTION

The testis is the site of synthesis of a wide variety of peptide hormones, including products of all three opioid peptide genes (Kilpatrick et al., 1986; Bardin et al., 1987; Garrett et al., 1989) and the so-called "stress-responsive" neuropeptide CRH (Thompson et al., 1987; Dunn et al., 1989). The stimulatory action of the hypothalamic CRH on POMC production and secretion in corticotrophs of the pituitary is well established *in vivo* and *in vitro* (Vale et al., 1981; Antoni, 1986; Lundblad et al., 1988). Therefore, we questioned whether there might be an analogous regulatory effect of CRH on POMC peptide within the testis.

In our initial studies in an *in vitro* system (i.e. removed from cell-cell interaction of the intact organ), CRH was found to stimulate  $ir\beta EP$  secretion from primary adult Leydig cells (Eskeland et al., 1989) (chapter II). The effective concentration for half maximal response ( $EC_{50}$ ) for this action of CRH was approximately  $0.7 \times 10^{-9}$  M, similar to the  $K_d$  of  $0.76 \times 10^{-9}$  M for CRH in the anterior pituitary reported by Wynn *et al.* (1983). The action of CRH was reversible by the CRH antagonist  $\alpha$ -helical CRH-(9-41). These studies suggest the presence of a CRH/POMC stimulus/response system in the testis similar to that in the hypothalamus/pituitary axis.

A possible function for CRH in the intact testis has not been examined to date. Therefore, the current study evaluated the intratesticular action of CRH on  $ir\beta EP$  secretion in the whole animal. In addition, we examined the effect of CRH on TIF,

which is a physiologically important compartment of the testis in which it acts as a vehicle through which factors are transported to regulate testicular function (Sharpe et al., 1983a).

It is well documented that POMC peptide expression and secretion in the testis are regulated (Chen et al., 1988; Valenca et al., 1986). A POMC mRNA containing a region that encodes for an amino terminal signal peptide is necessary for regulated secretory peptides (Gumbiner et al., 1982). The testis expresses a short POMC-like mRNA of approximately 900nt in length (Chen, 1987). This POMC mRNA which is orders of magnitude lower than in the pituitary, is about 200nt shorter than the full POMC transcript in the pituitary. It lacks exon 1 and 2 of the POMC gene and hence, the region that encodes for the amino terminal signal peptide present in the pituitary POMC mRNA (Jeannotte et al., 1987). Lacaze-Masmonteil *et al.* (1987) were able to detect the pituitary-like POMC mRNA in human testis. Only short POMC-like transcripts have been documented to date in the rat testis (Chen et al., 1984; Pintar et al., 1984; Gizang-Ginsberg et al., 1985; Bardin et al., 1987). Moreover, levels of POMC peptides in the testis are orders of magnitude lower than in the pituitary (Bardin et al., 1987). These testicular POMC peptides could be derived from low abundance full-length POMC transcripts. Therefore, we tested for the presence of a low abundance pituitary-like POMC mRNA in the rat testis.

### 3. MATERIALS AND METHODS

#### 3.1 *Chemicals and supplies*

Iodogen for RIA was obtained from Pierce (Rockford, IL). CRH,  $\alpha$ -helical CRH-(9-41) (CRH-(9-41)) and rat  $\beta$ EP were obtained from Peninsula Laboratories (Belmont, CA). The new CRH antagonist CRH-(12-41) ([DPhe<sub>12</sub>, Nle<sub>21,38</sub>, C $\alpha$ MeLeu<sup>37</sup>]rCRH(12-41)) was the kind gift of Dr. Jean Rivier at the Salk Institute. Urethane, Tween20 and all other chemicals were purchased from Sigma (St. Louis, MO). Immulon 2 removable ELISA wells were obtained from Baxter (Edison, NJ). [<sup>32</sup>P]CTP (800 Ci/mmol), [<sup>32</sup>P]dATP and <sup>125</sup>I-NaI was purchased from New England Nuclear (Boston, MA). Reverse transcriptase was purchased from Seika Gaku (Florida); Taq polymerase was obtained from Cetus-Perkins Elmer (San Diego, CA). Nusieve was obtained from FMC BioProducts (Rockland, ME); and Seakem agarose was purchased from IBI (NewHaven, CT). Iodogen was purchased from Pierce (Rockford, IL). The  $\beta$ EP antiserum (EP-3) was the generous gift of Anthony Liotta (NIH), and has been extensively characterized (Liotta et al., 1981). This antiserum recognizes  $\beta$ EP,  $\beta$ EP-(1-27),  $\alpha$ -N-acetyl derivative, and common precursor molecules.

#### 3.2 *Animals, surgical procedure and treatment*

Sprague-Dawley male rats [40-45 days (pubertal) and 70-75 days of age (adult)] were purchased from Charles River Laboratories (Wilmington, MA). Rats were housed in a temperature and light controlled room (12 h on/12 h off) with free access

to food and water for up to 2 days before use. The rats were anesthetized with urethane (1.3 g/Kg, i.p.), and a small incision was made in the scrotum. Direct intratesticular infusion of test substances was performed by cannulation of the testis using a 25 gauge needle connected to a PE-50 tubing. A microsyringe (Hamilton) mounted on an infusion pump (Gage) was used to infuse test substance over a 2 h period at a rate of 0.5  $\mu$ l/min. Assuming total TIF in the rat testis is 100  $\mu$ l (not more than 10% testicular weight) and that all the peptide is retained in the testis (no clearance), the maximum concentration of each test peptide after a fifteen minute infusion is approximately 1.5 nM (10 pmoles/min) to 4 nM (25 pmoles/min) in the testis. In each animal, the test substance was delivered in a saline solution containing 5 mg/ml each of BSA and ascorbic acid. The contralateral testis was infused with saline concurrently to serve as a control.

TIF was collected as described by Sharpe et al. (1983b) and Valenca et al. (1986) with some modifications. After the animals were decapitated, the testes were removed and a small incision was made in the caudal end of the testicular capsule, and each testis was placed inside a syringe barrel on a nylon mesh bed. TIF was allowed to drain overnight at 4°C into a microcentrifuge tube containing 10  $\mu$ l of 0.1 M acetic acid. Residual TIF was recovered by centrifugation at 400 x g for 10 min. TIF was then spun at 1000 x g at 4°C for 10 min and the supernatant was collected and its volume was measured.

### 3.3 *Extraction and radioimmunoassay*

Aliquots of TIF were diluted in the RIA buffer (0.1 M potassium phosphate buffer, pH 7.5 containing 0.1% gelatin and 0.2% Tween-20). The samples were heated at 100°C for 5 min to precipitate denatured proteins, spun at 4000g for 10 min and the supernatants were used in the assay.

Iodination and Plate RIA were described by Maidment et al. (1989). Briefly, 12 x 75mm tubes were coated with 50  $\mu$ l of iodogen in methylene chloride. The solvent was evaporated under a stream of nitrogen, and the tubes were stored dry at 4°C until needed. Carrier-free iodine was added to an iodogen-precoated tube containing  $\beta$ EP dissolved in 0.1 M potassium phosphate, pH 7.0. After 10 min the reaction mixture was diluted to 1-1.5 ml with 0.01 N hydrochloric and 0.10 N acetic acid (HCl-HOAc) solution, and loaded onto a Sep-pak reverse-phase column pre-equilibrated in the HCl-HOAc solution. The peptide was eluted with a methanol gradient (0, 10, 30, 75, 90%) in the HCl-HOAc solution. Iodinated  $\beta$ EP was eluted with the 75% methanol solution. Five  $\mu$ g  $\beta$ EP/100  $\mu$ Ci  $^{125}$ I was used.

In the plate RIA, Removawells were coated with 50  $\mu$ l of 1  $\mu$ g/ml protein A in 0.1 M sodium bicarbonate, pH 9.0, for 2 h at room temperature then washed 3 x 1 min with RIA buffer (0.2 M potassium phosphate, 0.1% gelatin, 0.2% Tween-20, pH 7.5). Buffer was added to the wells for another 30 min to remove any protein A that did not attach to the plate. Following 3 washes, 50  $\mu$ l of  $\beta$ EP antiserum (1:2000) was added for 1 h. The wells were then washed 3 x 2 min and then 50  $\mu$ l of  $\beta$ EP standards or samples were added overnight at 4°C. 50  $\mu$ l of  $^{125}$ I- $\beta$ EP was then added for 2 h at room temperature. The wells were washed 3 x 2 min with ice-cold

buffer, detached and put in 12 x 75mm tubes, and counted for 5 min each in a gamma counter.

#### **3.4 RNA isolation, reverse transcription (RT) and polymerase chain reaction (PCR)**

Total RNAs from adult rat pituitary, testis, and Percoll-purified Leydig cells were isolated using the guanidinium method described by Ulrich *et al.* (1977). For the subsequent experiments the amount of total RNAs were 4  $\mu$ g (pituitary), 10  $\mu$ g testis, 3.5  $\mu$ g Leydig cells, and 5  $\mu$ g yeast RNA. RT was performed essentially as described by Wang *et al.* (1989). PCR amplification was performed following the Cetus-Perkins Elmers protocol with few modifications. In a 20  $\mu$ l reaction volume, RT was performed on RNA samples (3 min denaturation at 95°C, 15 min annealing to 50 pmoles 3'end-primer at 55°C, and following the addition of 20 units of reverse transcriptase was added to each, samples were incubated for 30 min at 45°C). Ten  $\mu$ l of the samples were then directly amplified in a 50  $\mu$ l volume. The conditions for PCR were: 0.5 min denaturation at 95°C, 0.5 min annealing with 100 pmole each of the 3' and 5'end primer at 55°C, 1 min elongation with Taq polymerase at 72°C, 45 cycles. The 5'and 3'end-primers were 26nt and 25nt in length, respectively. The 5'end primer comprised the sense strand nucleotides from nucleotides 4 to 29 in exon 1, while the 3'end primer region was the antisense sequence from nucleotides 8 to 32 from the translation initiation site ATG in exon 2 of the POMC rat gene as described by Jeannotte and coworkers (1987). The unlabelled reaction mixture was processed for Southern blotting and hybridization as described below. PCR amplification was

also done on the rest of the samples using radioactive dATP as a tracer so that the amplified products could be directly analyzed for size on a 6% acrylamide gel.

### ***3.5 Riboprobe synthesis***

The pXBex1 plasmid containing the POMC cDNA insert was kindly provided by J.L.Roberts. The POMC cDNA insert comprised all of exon 1 to a BamH1 site in Intron A of the POMC gene. The plasmid was linearized with Xmn1 restriction enzyme. The linearized plasmid was extracted, precipitated and dissolved in water. Radioactive cRNA copies were synthesized at 37°C following the Promega protocol, using SP6 polymerase. The riboprobe synthesis yielded transcripts of 97nt in length containing 37 nucleotides in the 3' end of exon 1 and a portion of the first intron.

### ***3.6 Southern transfer and filter hybridization***

Amplified DNA samples were loaded on a 3% NuSieve/1% Seakem gel. DNA was transferred to Gene Screen Plus filter (NEN, Boston) and hybridized with the riboprobe as described elsewhere (Maniatis et al., 1989), except that 400 mM Pipes, pH 6.7 was used instead of Tris buffer in the prehybridization and hybridization buffers. The filter was hybridized overnight at 42°C and washed twice with 2x SSC (1x: 0.15 M NaCl, 0.015 M Na citrate) at room temperature and twice at 37°C for 15 min. The filter was exposed overnight to X-ray film at -70°C.

### ***3.7 Statistical analysis***

Comparison of ir $\beta$ EP levels in hormone-treated and untreated testes used paired t-test and Anova where appropriate. The level of significance chosen was  $p < 0.05$ .

## 4. RESULTS

### 4.1 The effect of CRH on ir $\beta$ EP levels in TIF *in vivo*


Dilution curves were obtained for ir $\beta$ EP in TIF of untreated pubertal and adult rats. The graph in Figure 6 shows dilution curves parallel to the standard curve, demonstrating that the antiserum recognizes a  $\beta$ EP-like peptide in the TIF of both pubertal and adult rats. The intra-assay coefficient of variation was less than 10%.

In the pubertal rat, CRH (10 pmoles/min for 2 h) caused an increase in the ir $\beta$ EP concentration in TIF by three-fold (Figure 7A) ( $p = 0.002$ ). The competitive antagonist CRH-(9-41) (10 pmoles/min) also stimulated ir $\beta$ EP levels in TIF, as shown in Figure 7B ( $p = 0.04$ ). When the pubertal animals were treated with CRH in the presence of the competitive antagonist CRH-(12-41) (10 pmoles/min), ir $\beta$ EP levels were, on average, below control (Figure 7C) ( $p = 0.03$ ). Figure 7D is a summary of CRH effect in pubertal rats as percent ir $\beta$ EP stimulation.




In contrast to findings in pubertal animals, in the adult rat, neither CRH (10 pmoles/min), CRH-(9-41) (25 pmoles/min) nor CRH-(12-41) (10 pmoles/min) had any effect on ir $\beta$ EP levels in TIF as shown in Figures 8A, B, and C respectively ( $p > 0.05$ ). Figure 8D shows the effect of CRH and its antagonists on the percent ir $\beta$ EP stimulation in adult rats.

TIF volumes in the pubertal and adult animals were unchanged when the different peptides were administered ( $p > 0.05$ ). The average TIF volumes were  $23.512 \pm 2.831$  ( $\mu\text{l} \pm \text{SE}$ ;  $n = 23$ ) and  $31.466 \pm 4.813$  ( $n = 18$ ) in pubertal and adult testes,





**Figure 6. Parallel analyses of serial dilutions of TIFs from pubertal and adult Sprague-Dawley rats measured by rat ir $\beta$ EP RIA. Std curve, synthetic rat  $\beta$ EP standard curve.  $B/B_0$ , bound to free ratio. The sample dilution curves have been displaced on the abscissa for display purposes.**



**Figure 7.** Effect of CRH and its antagonists on ir $\beta$ EP levels in TIF of pubertal rat. Each rat had one of its testes infused with saline as control. A, CRH vs. saline, n = 9. B, CRH-(9-41) vs. saline, n = 7. C, a mixture of CRH and CRH-(12-41) vs. saline, n = 7. D, Effect of CRH and its antagonists on the percent ir $\beta$ EP stimulation. Values in D are the mean  $\pm$  SE (n = 7-9 animals/group). \*, p < 0.01 ; \*\*, p < 0.05.



**Figure 8.** Effect of CRH and its antagonists on ir $\beta$ EP levels in TIF of adult rat. Each rat had one of its testes infused with saline as control. A, CRH vs. saline, n = 6 (n = number of animals). B, CRH-(9-41) vs. saline, n = 6. C, CRH-(12-41) vs. saline, n = 6. D, Effect of CRH and its antagonists on the percent ir $\beta$ EP stimulation. Values in D are the mean  $\pm$  SE (n = 6 animals/group).




respectively.

#### 4.2 Pituitary-like POMC mRNA in the rat testis


RNA samples isolated from adult rat testis and from an enriched adult Leydig cell preparation were analyzed for the presence of a pituitary-like POMC mRNA that could encode a prohormone for secreted peptides. To identify this RNA species, which if present, is in very low abundance, a sensitive detection method was used. First, cDNA synthesis was carried out on total RNA samples using an oligonucleotide primer complementary to a portion of the mRNA from exon 2, then the DNA product was itself copied using a sense-strand exon 1 primer. DNA products were amplified by repeated denaturation, priming, and synthesis. The expected size of the product generated from pituitary POMC mRNA is 147bp (Drouin et al., 1985). This is readily distinguishable from the ~ 3 Kb (kilobase) product generated from genomic DNA contamination in the RNA sample that could serve as a template in the amplification reaction.

To further verify that the 147bp band did indeed represent the 5'end of the POMC mRNA, unlabelled amplified DNA was subjected to Southern blot hybridization. The hybridization probe contained a 37bp sequence at the 3'end of exon 1, and therefore detected a product lying between, but not including the primers used for amplification. Radioactive amplified DNAs from adult rat pituitary, testis, Leydig cells, and yeast (negative control) were analyzed on acrylamide gel to determine the size of the amplified products. Pituitary, testis, and Leydig cells revealed bands that

**Figure 9.** Analysis of the RT/PCR products using [<sup>32</sup>P] POMC riboprobe for hybridization, after Southern transfer. **A**, diagram of exons 1 and 2 of the POMC gene. The CRH riboprobe (↔) contains a 37nt region in Exon 1 and 60nt into Intron A. The 5'end primer (→) comprises the region from nucleotides 4 to 29 in exon 1, while the 3'end primer (←) comprises the region from nucleotides 8 to 32 from the translation initiation site ATG in exon 2 of the POMC rat gene. **B**, size analysis of the RT/PCR products. 22 μg of the amplified DNAs were loaded on a 6% acrylamide gel. The gel was exposed to x-ray film for 20 min with two intensifying screens. Lanes: P, pituitary; T, testis; L, Percoll-purified adult Leydig cells; Y, yeast RNA. Hinf1 cut PBR plasmid (marker) is in the far right lane. **C**, gel with RT/PCR products detected by hybridization with the riboprobe. The amplified products were extracted with phenol/sevag (chloroform:isoamyl alcohol, 24:1), followed by ethanol precipitation. The samples were dissolved in 50 μl TE (10 mM Tris, pH 8.0, 0.1 mM EDTA). 25 μl of the samples were loaded on the gel. Total rat RNAs were used in the experiments. Lanes: 1, pituitary, 4 μg; 2, Leydig cells, 3.5 μg (lost quite a bit in the loading); 3, testis; 10 μg; 4, yeast, 5 μg; 6, Hinf1 cut PBR plasmid as marker, 3 μg. The autoradiograph shown was exposed overnight to x-ray film.



A



B

C

were 147 bp in length, which is the expected length for that region of the pituitary POMC mRNA (Figure 9B). Figure 9A shows the location of the primers and riboprobe in the POMC gene. Figure 9C shows the result of the Southern blot and hybridization with the riboprobe. Pituitary, testis and Leydig cells (the band is faint due to loss of sample during gel loading) show hybridization with the riboprobe. There is no band detected in the yeast lane.

## 5. DISCUSSION

We conclude that CRH can have a local physiological effect on ir $\beta$ EP secretion in the pubertal rat testis. That CRH is acting through specific receptors is suggested by the fact that ir $\beta$ EP release is stimulated following infusion of CRH, and by the response to the antagonist CRH-(12-41) in blunting CRH's effect in the pubertal rats. In addition, the data suggest the presence of an endogenous CRH since the antagonist was able to decrease ir $\beta$ EP levels to lower than basal. Ulisse *et al.* (1989) have shown CRH binding sites in Leydig cells and CRH inhibited chorionogonadotropin hormone-stimulated testosterone levels in primary Leydig cell cultures. In addition, CRH stimulates ir $\beta$ EP secretion in adult primary Leydig cell cultures and immunoreactive CRH is localized in the interstitial and germ cells. These data suggest that CRH is acting on Leydig cells to stimulate secretion of ir $\beta$ EP in TIF. It is still possible, however, that the germ cells, through unknown mechanisms, may also respond to CRH stimulation of their  $\beta$ EPs secretion into the interstitium.

POMC peptides and CRH have been shown to be developmentally regulated in the testis. In the mouse and hamster, POMC peptides, which are under luteinizing hormone control, remain at low levels before puberty and increase to maximum after puberty (Bardin *et al.*, 1987). In addition, irCRH levels in the testis of the rat is high before puberty, drastically drops at the onset of puberty and rises to maximum during adulthood (Yoon *et al.*, 1988). Hypophysectomy drastically decreases testicular

irCRH levels (Yoon et al., 1988).

Our results demonstrated that CRH and its antagonist CRH-(12-41) were able to affect ir $\beta$ EP levels in TIF in the pubertal rat but not in the adult. This difference may be due to various factors during testicular development that can modulate the behavior of CRH at different stages of testicular growth. This factor(s) may affect CRH synthesis or its receptor.

Developmental changes in hormone sensitivity as a consequence of changes in amounts of specific receptors have been documented for a few specific peptides. For example, luteinizing hormone and arginine vasopressin have altered receptor number and function at different ages of the rat testes (Audhya et al., 1987; Tahri-Joutei et al., 1989b). It has been reported that seminiferous tubules at different stages of their cycle can influence Leydig cell morphology and function and gonadotropin binding (Risbridger et al., 1981; Sharpe et al., 1990).

Our results showing that CRH and its analogs had no effects on TIF  $\beta$ EP levels in the adult rat were unexpected, given that adult rat Leydig cells are quite responsive to CRH *in vitro* (Eskeland et al., 1989). The methodological explanation for the lack of such effects in the adult such as inactive CRH, was ruled out in three ways: 1) most of the individual experiments tested both pubertal and adult rats in parallel; in these studies the pubertal animals were responsive. 2) The bioactivity of the CRH batches was further confirmed by its ability to stimulate  $\beta$ EP secretion from AtT20 cells (CRH-responsive POMC-producing mouse pituitary tumor cells). 3) The CRH batches were further analyzed on HPLC for their intactness. Therefore, we speculate

that the factors that could play an important role in cell-to-cell communication in the intact testis are removed in culture systems with serum-free media. A similar phenomenon has been observed for vasopressin in which it was able to stimulate steroidogenesis production in adult Leydig cell cultures but not in the intact testis, when injected intratesticularly (Sharpe et al., 1987). Similarly, oxytocin was able to inhibit hCG-stimulated testosterone production by mixed testicular cells (Adashi et al., 1984), while *in vivo*, it had no effect (Sharpe et al., 1987).

It is of interest to point out that the CRH antagonist CRH-(9-41) acted as a weak agonist in the current *in vivo* studies while in primary adult rat Leydig cell cultures, CRH-(9-41) acted as an antagonist (Eskeland et al., 1989)(chapter II). Winslow *et al.* (148) reported agonist effects for CRH-(9-41) in behavioral experiments on monkeys. Due to different environments in the two systems, cells may be more sensitive to certain agents in intact organ versus dispersed cells.

TIF volumes have been reported to alter in response to LH and LHRH (Sharpe et al., 1983b; Valenca et al., 1986), suggesting that gonadotropins may play a role in osmoregulation and capillary wall permeability in the testis. Our studies suggest that neither CRH, nor its antagonists play a role as osmoregulators or regulate capillary wall permeability.

Our POMC mRNA results demonstrate that the rat testis, including the Leydig cells, have a low but detectable levels of pituitary-like POMC mRNAs. The short POMC-like mRNA detected in the rat testis by different investigators mentioned earlier is capable of being translated into a protein that recognizes  $\beta$ EP antisera

(Clark et al., 1990). This short transcript is missing the signal peptide coding region. Recently, Clark and coworkers (1990) demonstrated in transfection studies using GH<sub>3</sub> cells, the cells expressing the full-length mRNA secreted irACTH and ir $\beta$ EP. Cells expressing the short transcript secreted neither of these peptides. Their results suggest that the full-length POMC mRNA may be necessary for normal peptide processing and secretion. It is possible that the POMC protein cannot be further processed for storage and secretion; therefore, our results suggest that the ir $\beta$ EP detected in TIF may come from the long pituitary-like POMC mRNA in the testis.

In conclusion, these studies indicate that CRH may be important in maintaining normal testicular reproduction. Further studies must be conducted to understand the mechanisms and conditions in which CRH is involved locally in regulating steroidogenesis or spermatogenesis *in vivo*.

**IV. THE EFFECT OF TEMPERATURE ON THE ACTION OF  
CRH ON IR $\beta$ EP SECRETION IN TWO CELL LINES: TM3 AND  
AtT20**

**N. L. Eskeland, B. S. Schachter**

**Departments of Pharmacology (N.L.E.), Obstetrics, Gynecology, and Reproductive  
Science, and Anatomy (B.S.S.), Mount Sinai Medical School,  
New York, N.Y.**

## 1. ABSTRACT

Testicular function is sensitive to chemical and thermal stresses. CRH and POMC, two peptide hormones that are involved in the body's neuroendocrine stress-response system are produced in the testis. We have recently documented that CRH stimulates secretion of  $\beta$ EP, a POMC peptide, from adult primary rat Leydig cells. To investigate the effects of small temperature changes on the CRH/POMC system using the reverse hemolytic plaque assay, we employed TM3 cells, a mouse prepubertal Leydig cell line that secretes ir $\beta$ EP and responds to CRH. In cultures treated with  $\beta$ EP antiserum (diluted 1:50) and complement (diluted 1:25), ~14% of the cells formed plaques. Increasing concentrations of CRH increased mean plaque area by 65% and percentage of plaque-forming cells by 60%. Very few plaques were formed around CRH-treated cells preincubated with  $\beta$ EP antiserum and  $\beta$ EP. The median effective concentration ( $EC_{50}$ ) of the CRH dose-response curve at 34°C (testicular temperature in rodents) and 37°C (normal body physiological temperature) were  $10^{-10}$  M and  $10^{-9}$  M, respectively, for the total plaque area/100 cells. AtT20 cells, a pituitary tumor mouse cell line, were also treated with CRH at both temperatures. Using a radioimmunoassay to measure ir $\beta$ EP levels in the media, the  $EC_{50}$ s for the CRH dose-response curve at 34°C and 37°C were  $2 \times 10^{-10}$  M and  $2 \times 10^{-9}$  M, respectively, at 1 h. After 3.5 h the 34°C CRH dose-response curve shift was still observed. These results suggest that CRH receptors or post-receptor actions are sensitive to small temperature changes.

## 2. INTRODUCTION

The testes of many mammals reside in the scrotum, which serves as a thermoregulator that is apparently essential for normal male reproduction. The temperature of the scrotum is few degrees lower than the body's physiological temperature of 37°C. Temperature elevation from normal scrotal temperature to 37°C impairs germ cells (Chowdhury et al., 1970). Cryptorchidism (the translocation of testis to the abdomen) changes morphology and functions of germ, Sertoli and Leydig cells (Risbridger et al., 1981; Jegou et al., 1983; Lunstra et al., 1988). In the adult rat testis, hydrolytic enzyme activity (Blackshaw et al., 1978) and DNA synthesis (Fujisawa et al., 1988) decrease. In addition, DNA, RNA and protein syntheses in human testes are sensitive to temperature changes (Nakamura et al., 1988). Receptor number for gonadotropins, prolactin (Huhtaniemi et al., 1982), estrogen (Damber et al., 1983) and vasopressin (Tahri-Joutei et al., 1989a) are altered in response to thermal changes. Moreover, Leydig cells undergo hypertrophy and are hyperresponsive to luteinizing hormone-mediated testosterone secretion *in vitro* (Iturriza et al., 1979; Risbridger et al., 1981).

CRH, the potent hypothalamic hormone (Vale et al., 1981), is also made in the testis (Thompson et al., 1987; Yoon et al., 1988; Audhya et al., 1989). Recently, we have demonstrated that CRH stimulates the secretion of  $\text{ir}\beta\text{EP}$ , a POMC peptide, from primary rat Leydig cells where the POMC hormone is synthesized (Eskeland et al., 1989)(chapter II). We proceeded to determine the effect of temperature changes

on this CRH/POMC system to better understand the role of thermal stress on normal testicular function. In addition, we also tested a non-testicular cell line that has the CRH/POMC system in order to assess the effect of temperature on CRH action on POMC in general. TM3, a prepubertal non-tumor forming POMC-producing mouse Leydig cell line (Mather, 1980; Bardin et al., 1987), as well as AtT20, an anterior pituitary tumor mouse cell line that secretes POMC peptides and responds to CRH (Affolter et al., 1985; Rosendale et al., 1987), were used in the secretion studies.

We used the RHPA in our studies on TM3 cells since it allows for the detection of low levels of ir $\beta$ EP from individual cells. We employed the plate RIA to measure ir $\beta$ EP in media from AtT20 cells since these cells secrete large amounts of POMC-derived peptides. Plate RIA was chosen over conventional RIA because this assay requires fewer steps and is very sensitive.

### 3. MATERIALS AND METHODS

#### 3.1 *Chemicals and supplies*

CRH,  $\alpha$ -helical CRH-(9-41), human and rat  $\beta$ EP were obtained from Peninsula Laboratories (Belmont, CA); guinea pig complement, penicillin-streptomycin, sterile saline, Dulbecco's Modified Eagle's Medium (DMEM) and DMEM/HAM F12 were obtained from Gibco (Grand Island, NY); Staphylococcal protein-A, poly-L-lysine, BSA, chromium chloride hexahydrate, paraformaldehyde, potassium phosphate dibasic, sodium bicarbonate, gelatin, and Tween20 were purchased from Sigma (St. Louis, MO); sheep blood preserved in modified Alsever's solution was obtained from Rockland (Gilbertsville, PA); Immulon 2 removable ELISA wells were obtained from Baxter(). The  $\beta$ EP antiserum was the generous gift of A. Liotta (NIH), and has been extensively characterized (Liotta et al., 1981).

#### 3.2 *Cell culture conditions*

TM3 cells (ATCC,) were cultured in a 1:1 DMEM/HAM F12 media containing 5% horse serum and 2.5% fetal bovine serum and streptomycin-penicillin (10 units penicillin, 10  $\mu$ g streptomycin). AtT20 cells (D16-16), kindly provided by Dr. James Roberts, were maintained in DMEM medium with 10% fetal bovine serum and antibiotics. Both cell lines were incubated in a 95% air / 5% CO<sub>2</sub> humidified at 37°C. Experiments conducted at 34°C used cells that were pre-incubated overnight at 34°C.

For the experiments, TM3 cells were harvested at subconfluency with a rubber policeman. RHPA was done on these cells as described below. AtT20 cells were plated in a 24 well plate at a concentration of  $3 \times 10^4$  cells/0.5 ml/well, and cultured for 4 days before use. On the day of the experiment, AtT20 cells were washed 2 x with serum-free DMEM media containing 0.1% BSA and antibiotics. The cells were preincubated at the desired temperatures for 1 h; then CRH at different concentrations was added. The cells were incubated for the times indicated. Media were collected and frozen at  $-70^{\circ}\text{C}$  until assayed. Cells were then washed twice with saline and 500  $\mu\text{l}$  of 0.1% sodium dodecyl sulfate was added to the cells to lyse them. The lysates were frozen at  $-20^{\circ}\text{C}$  until DNA determination was done using the method described by Hinegardner *et al.* (Hinegardner, 1971).

### 3.3 RHPA

The RHPA was performed as previously described (Smith *et al.*, 1986). During the 3.5 h incubation, chambers received hourly media changes to ensure the continued presence of undegraded CRH. After 3.5 h the complement was added and all samples were incubated at  $37^{\circ}\text{C}$  for 1 h. The reaction was stopped by infusing through the chambers 2% glutaraldehyde in saline. The slides were then stored in 0.1M phosphate buffer at  $4^{\circ}\text{C}$ .

### 3.4 Plate RIA

Iodination and Plate RIA was described by Maidment *et al.* (1989). Briefly, 12 x

75mm tubes were coated with 50  $\mu$ l iodogen in methylene chloride. The iodogen was allowed to dry through a stream of nitrogen, and the tubes were stored dry at 4°C until needed. 5  $\mu$ g  $\beta$ EP /100  $\mu$ Ci  $^{125}$ I was used. The iodination procedure and plate RIA were described in chapter III.

### 3.5. *Quantitative analysis*

For the RHPA, the analysis was performed using Axiomat Image Analyzer System, and the plaque areas were calculated using the Drexel analysis program (Feingold et al., 1986). In each experiment, chambers without antagonist were assayed in duplicate, while each condition with antagonist was tested in a single chamber. All measurements and statistical analyses were done as previously described (Eskeland et al., 1989) (chapter II).

For the plate RIA, statistical analysis was carried out by analysis of variance and student paired t-test. The level of significance chosen was  $p < 0.05$ .

## 4. RESULTS

### 4.1 The effect of CRH on irβEP secretion from TM3 cells

Three rodent Leydig cell lines were tested for production of secreted irβEP. Only the mouse TM3 cell line, but not the rat R2C or LC540 cell lines, produced detectable levels of secreted peptide. Therefore, the TM3 were used for all subsequent studies.

Secretion of irβEP from TM3 cells was examined in the presence of CRH with or without its competitive antagonist α-helical CRH-(9-41)(10<sup>-6</sup>M) for 3.5 h. Parallel experiments were done at 34°C (normal testicular temperature) and 37°C (the body's physiological temperature). As seen in Figures 10A through 10D, in which the experiments were done at 37°C, increasing concentrations of CRH significantly increased mean plaque size by approximately 70% and the percentage of plaque-forming cells by 10-15% ( $p < 0.01$ ). In contrast, cells cultured in the presence of the antagonist showed no CRH-related increase in either mean plaque area or the percentage of plaque-forming cells above the basal levels (no treatment) ( $p > 0.05$ ). Similarly, Figures 10C and D, in which the incubations were done at 34°C, show a CRH dose response curve in which CRH significantly stimulated mean plaque area (~ 70%) and the percentage of cells forming plaques by 10-15% ( $p < 0.01$ ). It should be noted that at 34°C, lower concentrations of CRH than those at 37°C were able to maximally stimulate the mean plaque area and the number of plaque-forming cells. The effect of  $1 \times 10^{-9}$  M CRH at 34°C was higher than the effect at 37°C ( $p$

= 0.002). In addition, at 34°C, when the antagonist was added with CRH it significantly inhibited CRH's effect but not to basal levels at the highest CRH concentration ( $10^{-7}$  M).


For negative controls, very few plaques were seen in chambers tested with antiserum preincubated overnight at 4°C with 2  $\mu$ g synthetic human  $\beta$ EP/ $\mu$ l antiserum. No plaques were seen in chambers lacking  $\beta$ EP antisera or complement.

Figure 1E shows CRH dose-response curves at 34°C and 37°C on the total plaque area (mean plaque area x percent plaque-forming cells) in 100 cells. At 34°C, the  $EC_{50}$  is  $1 \times 10^{-10}$  M while at 37°C, the  $EC_{50}$  is  $1 \times 10^{-9}$  M.



#### 4.2 The effect of CRH on ir $\beta$ EP secretion from AtT20 cells

We next tested a non-Leydig cell line in which ir $\beta$ EP secretion is stimulated by CRH to see if the temperature sensitivity is restricted to cells of the testis. We chose AtT20 pituitary cell line since it is well established that these cells have CRH receptors and that CRH stimulates POMC peptide secretion from these cells (Rosendale et al., 1987). Figure 2A shows CRH dose-response curves on ir $\beta$ EP release to the media at both 34°C and 37°C for 1 h. The dose-response curve at 34°C gave an  $EC_{50}$  of  $2 \times 10^{-10}$  M and at 37°C the  $EC_{50}$  was  $2 \times 10^{-9}$  M. A quantitatively similar result was observed following a 3.5 h stimulation. Figure 2B shows differences at both temperatures, with  $EC_{50}$ s of  $0.8 \times 10^{-9}$  M, and  $5 \times 10^{-9}$  M at 34°C and 37°C respectively. Similar to results with TM3 cells, the effect of CRH at  $1 \times 10^{-9}$  M was higher at 34°C than at 37°C ( $p = 0.006$ ; statistical analysis done

**Figure 10.** Dose-response curve of CRH effects on mean plaque size and the percentage of plaque-forming cells in TM3 cells. The RHPA was performed for 3.5 h at 37°C (A,B) and 34°C (C,D). A,C, values in the top curves represent the mean  $\pm$  SE of determinations made from 40-60 plaques in duplicate chambers; values in the lower curves (+ CRH-(9-41)) represent the mean  $\pm$  SE of determinations made from 20-30 plaques in a chamber. B,D, values in the top curves represent the average of two determinations made from at least 150 cells/chamber in duplicates; values in the lower curves (+ CRH-(9-41)) represent the percentage of plaque-forming cells in a chamber. The responses to CRH and the CRH antagonist in this experiment are representative of at least two separate RHPAs. E, effect of CRH on the combination of plaque area and percentage of plaque-forming cells at 37°C and 34°C; the values represent mean plaque area x the percentage of plaque-forming cells per 100 cells.



**Figure 11. Dose-response curve of CRH effects on ir $\beta$ EP release from AtT20 cells at 1 h (A) and 3.5 h (B) at 37°C and 34°C. Values represent the mean  $\pm$  SEM of triplicate chambers. The 3.5 hr values are representative of at least three separate experiments.**



on the combination of three separate experiments).

## 5. DISCUSSION

The data obtained provide evidence that TM3 cells actively secrete ir $\beta$ EP and that this action is specifically stimulated by CRH. Therefore, this cell line provided a convenient *in vitro* system for analyzing the temperature sensitivity of Leydig cell responsiveness to CRH.

The experiments were conducted for 3.5 h since these cells secrete low levels of ir $\beta$ EP and at shorter times the plaques are small and difficult to analyze. In RHPAs, the plaque size gets larger over time, an indication that the cells are viable and are continuously secreting the peptide of interest (Smith et al., 1986).

Both TM3 cells, a testicular cell line, and AtT20 cells, a pituitary cell line, showed greater sensitivity to CRH at 34°C than at 37°C. In the RHPAs with TM3, fresh CRH was infused into the chambers every hour to insure full CRH activity in our system because Ulisse and coworkers (1989) demonstrated that in adult Leydig cell cultures, about 50 % of the added CRH is degraded after a one hour incubation at 37°C.

The effect of temperature on CRH action was higher at 1 h than at 3.5 h (10-fold vs. 6-fold). These results suggest that the difference in sensitivity of cells to CRH is not merely due to more rapid degradation of CRH at the higher temperature.

Thermal regulation of the testis is critical for both testosterone production and spermatogenesis in the adult mammal. The cellular mechanisms responsible for testis sensitivity to small temperature changes are unknown. There is not much

documentation on tissues other than testes regarding cellular responses to effectors during hypothermia or hyperthermia. Vescovi and coworkers (1990) have shown in humans that during hyperthermia, POMC-derived peptide levels in the blood were raised, and the effect was selective since there was no corresponding increase in circulating levels of enkephalin. While in guinea pig, Nakane and coworkers (1985) reported CRH-dependent stimulation of ACTH levels in plasma in response to hypothermia. Our results suggest that CRH receptors or post-receptor mechanisms are sensitive to temperature changes. The observation made may only occur in dispersed cells and not in the intact organ, therefore, the physiological relevance of this phenomenon needs to be determined.

The  $EC_{50}$  for CRH dose-response curve at 34°C for the TM3 cells was similar to the  $k_d$  for CRH in Leydig cell membranes ( $1.3 \times 10^{-10}$  M) reported by Ulisse *et al.* (1989), suggesting that 34°C may be the optimum temperature for the action of CRH in the testis. In the AtT20 data, the  $EC_{50}$ s at 34°C and 37°C after 3.5 h were higher than the  $EC_{50}$ s at 1 h. It is possible that some CRH degraded at both temperatures after 3.5 h.

The results of the full dose-response curves generated in our studies demonstrated the importance of such curves in determining the sensitivity of cells to agents under certain conditions. Using doses of drugs that would give maximum response is not sufficient to determine fully the effect of such a drug on target cells. Had we used only the maximum doses of CRH, we would have erroneously concluded that temperature changes have no effects on the action of CRH. Moreover, submaximal

concentrations are probably more physiologically relevant since endogenous modulators are themselves under regulation.

**V. LOCALIZATION OF CRH mRNA IN THE TESTIS BY *IN SITU*  
HYBRIDIZATION**

**N. L. Eskeland, B. S. Schachter**

**Departments of Pharmacology (N.L.E.), Obstetrics, Gynecology, and Reproductive  
Science, and Anatomy (B.S.S.), Mount Sinai Medical School,  
New York, N.Y.**

## 1. ABSTRACT

The hypothalamic peptide CRH is the principal stimulator of the synthesis and secretion of POMC-derived peptides in the anterior pituitary. Both CRH and POMC gene expression have been documented in other tissues in the body such as the testis and placenta. Moreover, CRH has been shown to stimulate secretion of POMC peptides from testicular Leydig cells and from placental fragments cultured *in vitro*. Therefore, it appears that CRH serves a paracrine and/or autocrine function in regulating the POMC system in a number of organs.

In the rat testis, immunoreactive CRH has been localized, in one study, exclusively in interstitial cells, and in another study, in both the interstitium and in germ cells. However, the specific site(s) of CRH synthesis in this organ has not been determined. Therefore, we have investigated the site(s) of local synthesis of this peptide in the rat testis using the method of *in situ* hybridization to localize CRH mRNA. The probe used was a digoxigenin-labelled CRH riboprobe of approximately 700bp in length. Our studies showed an intense staining in the periphery of the tubules in which spermatogonia and primary spermatocytes reside. In addition, a number of tubules also had secondary spermatocytes and spermatids that stained. Positive staining was not obvious in Sertoli or interstitial cells. As a positive control, in the olfactory bulb, almost all cells stained as previously documented. Digoxigenin-labelled CRH sense strand RNA riboprobe showed no staining in either the testis or olfactory bulb. To further verify that the probe was specifically hybridizing to CRH mRNA, competition

studies were carried out: Sections that received excess unlabelled CRH riboprobe in addition to the labelled CRH riboprobe stained less strongly than those sections in which only digoxigenin-labelled CRH riboprobe was used. In addition, a section in which the labelled riboprobe was added with an excess of unlabelled estrogen receptor mRNA riboprobe (i.e. a heterologous RNA) showed staining intensity similar to the sections with only labelled CRH riboprobe. These results suggest that the germ cells are the predominant synthesizers of CRH mRNA.

## 2. INTRODUCTION

A number of peptides appear to have paracrine roles in the testis (Sharpe et al., 1987). For example, inhibin and LHRH-like peptide, which are primarily made in Sertoli cells, regulate testosterone production in Leydig cells (Sharpe et al., 1981, 1983b, 1987; Morris et al., 1988; Franchimont et al., 1989). POMC-derived peptides, which are synthesized in Leydig cells, primary spermatocytes and spermatogonia (Pintar et al., 1984; Cheng et al., 1985; Gizang-Ginsberg et al., 1985), regulate androgen-binding proteins and Sertoli cell proliferation (Boitaini et al., 1986; Orth, 1986). In addition, the hypothalamic peptide CRH is synthesized in the testis (Thompson et al., 1987), and it acts on Leydig cells to stimulate  $\text{ir}\beta\text{EP}$  secretion (Eskeland et al., 1989)(chapter II) and to inhibit gonadotropin-stimulated testosterone release (Ulisse et al., 1989).

The site(s) of testicular CRH synthesis is unknown. IrCRH has been localized in interstitial and germ cells (Yoon et al., 1988). In cultures of enriched preparation of Leydig cells, irCRH is detected in the media as well as in the cell (Fabbri et al., 1990), suggesting that CRH is synthesized in these cells. In addition, translocation of the testis to the abdomen drastically decreases irCRH in the testis (Yoon et al., 1988). These reports suggest, but do not prove, that germ and Leydig cells of the testis are the source of CRH. In this paper, we attempted to determine possible origin(s) for CRH in the rat testis by using *in-situ* RNA/RNA hybridization technique to localize the site(s) of CRH mRNA.

### 3. MATERIALS AND METHODS

#### 3.1 *Tissue preparation*

The procedure for tissue preparation and *in-situ* hybridization was previously described in Shivers *et al.* (1989) with few modifications: Testes and olfactory bulbs were removed from adult male Sprague-Dawley rat and frozen in crushed dry ice for 2 h. Tissues were mounted on microtome chucks using OCT compound (Optimum Cooling Temperature) and kept in a cryostat microtome at -15°C for two hours before cutting. Ten-micron sections were cut and adhered onto silanized (TESPA; Sigma) precleaned slides and transferred to clean slide boxes on dry ice until fixation time. The sections were then fixed for 5 min in 3 % paraformaldehyde in phosphate buffered saline in which diethylpyrocarbonate (DEPC, a ribonuclease inhibitor) (Sigma, St. Louis, MO) was added. The slides were then rinsed twice in PBS, and dehydrated in graded alcohol. The slides were stored with dessicant capsules at -70°C. Care was taken to insure that all solutions for fixation and *in-situ* hybridization were ribonuclease-free.

#### 3.2 *Digoxigenin-labelled riboprobe synthesis*

The PGEM-3Z plasmid containing a CRH cDNA insert 759bp (bp, base pair) was the generous gift of Dr. Robert Thompson (University of Michigan). The CRH cDNA insert comprised the region of exon 2 of the rat CRH gene, from position

1227bp to position 1986bp (Thompson et al., 1987). The plasmid was linearized with either HindIII (for antisense riboprobe) or EcoR1 (for sense riboprobe) restriction enzyme, extracted with phenol/chloroform, precipitated with ethanol and dissolved in TE (10 mM Tris, pH 8.0, 1 mM EDTA). For riboprobe synthesis in a 20  $\mu$ l reaction, ~200 ng of the plasmid was used. Digoxigenin-UTP (DIG-UTP)-labelled probes were synthesized using the protocol described by Springer *et al.* (in press) (final concentration: 1x transcription buffer, 10mM DTT, 40 units RNAsin, 400  $\mu$ M each of GTP, ATP, and CTP, 100  $\mu$ M UTP, 400  $\mu$ M DIG-UTP, 1  $\mu$ l of a diluted [ $^{32}$ P]UTP [New England Nuclear] to monitor synthesis, and 19 units T7 RNA or SP6 Polymerase [Promega]). The synthesis was done for 2 h at 37°C followed by a 10 min, 37°C DNA digestion with 1 unit of DNase and 40 units of RNAsin. Then, the mixture was adjusted to final concentration of 50 mM EDTA and 1x STE (1 M NaCl, 100mM Tris-HCl, pH 8.0, 10mM EDTA), 13.2 mM DTT and 25  $\mu$ g tRNA as carrier. The mixtures were ethanol precipitated, pellets were washed with 95 % ethanol and dissolved in 50  $\mu$ l DEPC-treated water. Aliquots of the riboprobes before and after precipitation were loaded on a 4 % acrylamide gel to monitor the intactness of the riboprobes. Serial dilutions of the riboprobes were spotted on a nitrocellulose paper and processed for alkaline phosphatase detection (described below) to confirm that the DIG-UTP was incorporated in the riboprobes.

### 3.3 *In situ* hybridization

Sections were removed from the -70°C freezer and allowed to thaw in a dessicator

for 30 min. Clear, viscous nail-polish (Wet and Wild, Revlon) was used to form barriers between sections receiving different treatments. The sections were incubated in 2x SSC (1x : 150 mM NaCl, 15 mM Sodium Citrate, pH 7.0) with 5  $\mu$ g/ml proteinase K for 10 min then rinsed twice in 2x SSC for 10 min. The slides were placed in a Nalgene utility box containing Whatmann 3MM filter paper saturated with 4x SSC, 50% formamide. Prehybridization and hybridization buffers were described by Shivers and coworkers (Shivers et al., 1989) except that 20 mM Pipes, pH 6.7 buffer was used instead of Tris. Preheated prehybridization buffer was added to the sections, and the boxes were kept in a humidified chamber for 2 h at 50°C. The prehybridization buffer was removed from the sections, and preheated hybridization (same as the prehybridization buffer except for 0.005% yeast total RNA and 0.01% herring sperm DNA) solution containing either 300 ng/ml antisense or sense CRH riboprobe or no riboprobe. Some sections had, in addition to the antisense CRH riboprobe, excess unlabelled antisense CRH or estrogen receptor riboprobe (3  $\mu$ g/ml) in the hybridization solution. Hybridization was carried out overnight at 50°C. The slides were then washed in 2x SSC for 45 min at room temperature. Thirty  $\mu$ g/ml RNase A in 0.5M NaCl, 10mM Tris pH 8.0 was added to the sections for 30 min. The slides were washed for 1 h in 2 liters 2x SSC at 50°C, 3 h in 4 liters of 0.1x SSC at 50°C followed by an overnight wash in the same solution at room temperature with gentle stirring.

### 3.4 *Detection*

The detection method was described in the Boehringer Mannheim protocol using the Dig Nucleic Acid Detection Kit (Boehringer Mannheim Biochemicals, Indianapolis, IN). After the overnight wash, the slides were incubated in 2x SSC, 0.05% Triton X-100 (Fisher Scientific, Orangeburg, N.Y.) containing 2% normal goat serum (Vector Laboratories, Burlingame, CA) for 2 h. The slides were then washed twice for 5 min in Buffer 1 (100mM Tris-HCL pH 7.5, 150 mM NaCl). The slides were placed in a box containing a Whatmann 3MM filter saturated with Buffer 1. Anti-digoxigenin-AP conjugate (diluted 1:400) in Buffer 1 containing 1% normal goat serum and 0.3% Triton X-100 was added to the sections and the box was placed overnight at 4°C. The slides were then washed once in Buffer 1 for 10 min followed by a 10 min wash in Buffer 2 (100mM Tris-HCl, pH 9.5, 100 mM NaCl, 50 mM MgCl<sub>2</sub>). The sections were incubated with Chromagen (freshly prepared in a dark bottle by adding 0.338 mg/ml Nitroblue Tetrazolium salt (NBT), 0.175 mg/ml 5-Bromo-4-Chloro-3-Indolyl Phosphate, Tolidinium salt (BCIP), 2.4 mg levamisole in Buffer 2) in a light tight box with paper saturated with Buffer 2 for 2 h, until color was developed. The reaction was stopped by rinsing the slides in Buffer 3 (10 mM Tris-HCl, pH 8.0; 1 mM EDTA). Sections were finally rinsed in water, nail polish was removed, and slides were coverslipped using Gel/Mount Tm (aqueous based mount, BIOMEDA Corp.). The slides were stored in a box at -20°C to minimize diffusion of the reaction product. At all times, care was taken not to let the sections dry out.

## 4. RESULTS

### 4.1 CRH mRNA in the testis


The digoxigenin-labelled CRH riboprobe showed intense staining of germ cells in the tubules as seen in Figure 12A. Figure 12B shows a negative control using digoxigenin-labelled sense strand CRH riboprobe. Only background staining is observed with that riboprobe. Figure 13A shows a higher magnification of the interstitial and germ cells. As shown in those figure, primary spermatocytes, spermatogonia and spermatids stained strongly with the antisense riboprobe; no staining was observed in the interstitial cells. The stained cells scattered in the interstitium appear to have the morphology of germ cells; these cells are probably from broken tubules.

### 4.2 Competition experiments and positive control


To further confirm that the riboprobe used was specific in its hybridization to CRH mRNA, testicular sections received a 10-fold molar excess of unlabelled antisense CRH riboprobe or excess (10x) unlabelled antisense estrogen receptor riboprobe in addition to the digoxigenin-labelled antisense CRH riboprobes. Figure 13B, in which a section received the excess unlabelled CRH riboprobe, stained less than the section in Figure 13C, in which the tissue received excess unlabelled estrogen receptor riboprobe.

As a positive control for CRH mRNA detection, olfactory bulb sections were tested

**Figure 12.** *In situ* hybridization staining of CRH mRNA in an adult rat testis using digoxigenin-labelled riboprobe. A, antisense CRH riboprobe. B, sense CRH riboprobe. Nomarski optics; magnification, x160




A




B

**Figure 13.** *In situ* hybridization staining of CRH mRNA in testis and olfactory bulb. A, interstitial cells of the testis and seminiferous tubules. ST, spermatid; SC, spermatocyte. Nomarski optics; magnification, x320. B,C, competition studies with digoxigenin-labelled antisense CRH riboprobe in a testis. B, excess unlabelled CRH antisense riboprobe and digoxigenin-labelled riboprobe in the testis. C, excess unlabelled estrogen receptor antisense riboprobe. D,E, olfactory bulb. D, antisense digoxigenin-labelled riboprobe. E, sense digoxigenin-labelled riboprobe. Bright field optics; magnification, x32.



A




B

C



D



E

in the same experiment. Figures 13D and E show sections that were treated with either the antisense labelled CRH riboprobe or with the sense labelled riboprobe, respectively. Figure 13D is positive for CRH mRNA labelling, while figure 13E is negative.

## 5. DISCUSSION

CRH-like mRNA has been found in the RNA extracted from rat testis (Thompson et al., 1987) and immunoreactive-like CRH peptide has been demonstrated in testis, suggesting that the testis is capable of synthesizing this neuropeptide. Audhya and coworkers (Audhya et al., 1989) detected irCRH only in interstitial cells, while Yoon and coworkers detected irCRH in the germ cells as well (Yoon et al., 1988). These conflicting documentations may be due to differences in antibody recognition of a CRH-like peptide. Fabbri and coworkers (Fabbri et al., 1990) reported irCRH in the media from Percoll-purified adult Leydig cells in culture, again suggesting that these cells synthesize the peptide. Our non-radioactive *in-situ* hybridization results demonstrated that spermatogonia, spermatocytes, and spermatids are the major sites of CRH mRNA. The *in situ* hybridization may not have been sensitive enough to detect low abundant CRH mRNA in interstitial cells.

In our previous studies, in which immunocytochemistry was used to restrict our analysis to Leydig cells, the CRH antagonist  $\alpha$ -helical-CRH-(9-41) did not lower basal ir $\beta$ EP levels, suggesting that the POMC-producing Leydig cells do not secrete CRH. In addition, Fabbri *et al.* (1990) reported irCRH levels in enriched Leydig cell preparations that were several hundred-fold lower than the irCRH levels in total testis extracts reported by Yoon *et al.* (1988). Assuming that there are approximately 10 million Leydig cells/ rat testis, the findings suggest that the major source of a CRH-like peptide in the adult rat testis is not Leydig cells but non-Leydig interstitial

cells and/or germ cells.

The riboprobe used in the *in situ* hybridization studies appears to be specific in its detection of CRH mRNA since excess unlabelled antisense CRH RNA was able to compete with digoxigenin-labelled riboprobe but excess unlabelled antisense estrogen receptor RNA (a heterologous RNA) was not able to compete. In addition, the digoxigenin-labelled sense CRH riboprobe gave negative results in both the testis and olfactory bulb tissues. The staining pattern in the olfactory bulb, using the digoxigenin-labelled riboprobe, was similar to the patterns seen in *in situ* hybridizations with radioactive CRH probes and immunocytochemical detection of CRH distribution in the rat olfactory bulb (Imaki et al., 1989).

Functional CRH receptors have been shown in enriched adult Leydig cell preparations. CRH stimulates  $ir\beta EP$  secretion (Eskeland et al., 1989) and inhibits luteinizing hormone-dependent stimulation of testosterone secretion in Percoll-purified Leydig cells (Ulisse et al., 1989). In addition, CRH stimulates  $ir\beta EP$  concentrations in testicular interstitial fluid in the whole animal at the pubertal age (NLE, CM, CC, BSS; chapter III). These reports suggest a local regulatory function for CRH in rat testis.

Cell-to-cell interactions in the testis are essential for the process of spermatogenesis. Different peptides such as oxytocin, inhibin, and LHRH-like peptide made in the Sertoli cells regulate the function of Leydig cells (Sharpe, 1984; Sharpe et al., 1986, 1987). In addition, depending on the stage of seminiferous tubules, Leydig cells have different morphology (Bergh, 1982); moreover, experimental cryptorchidism, which

depletes germ cells, alters Leydig cell function (Risbridger et al., 1981). The mechanisms by which cells communicate in the testis, especially communication between germ and interstitial cells are unknown.

## VI. GENERAL DISCUSSION

### A. CRH effect on ir $\beta$ EP secretion from Leydig cells of adult rat testis *in vitro*

CRH was able to stimulate ir $\beta$ EP secretion from Leydig cells in culture. The action of CRH was through specific receptors since the CRH antagonist  $\alpha$ -helical CRH-(9-41) was able to inhibit CRH-dependent stimulation of ir $\beta$ EP release. The RHPA method used to study ir $\beta$ EP secretion, followed by immunocytochemical identification of Leydig cells, provided a powerful tool to discriminate between secreting and non-secreting Leydig cells, at least in an *in vitro* system. In Percoll-purified Leydig cell cultures, only a subset of the monoclonal stained-cell population secreted ir $\beta$ EP and responded to a CRH stimulus.

The reason for this heterogeneity is not clear but may reflect position-dependent differences among these cells at the time they were removed from the testis. The presence of a Leydig cell cycle in the mammalian testis has been suggested by the work of Bergh (Bergh, 1982). Bergh documented that some Leydig cells with a decreased cell density were preferentially associated with seminiferous tubules mainly in the stages of spermatid elongation and maturation (Leblond et al., 1952), while Payne and coworkers (Payne et al., 1980) found two Leydig cell populations that differed in their responses to LH. In addition, Gizang-Ginsberg and Wolgemuth (1985) found expression of a POMC-like mRNA in Leydig cells preferentially associated with the tubule stages described above. Sharpe *et al.* (1983b; 1984)

suggested that factor(s) from the tubules are responsible for differences in Leydig cell morphology and function. Therefore, given this functional heterogeneity among Leydig cells, it may be that only a subset have CRH receptors. Ulisse *et al.* (1989) found that in an enriched Leydig cell preparation, there were very low levels of CRH receptors per cell (300/cell). Perhaps the true receptor distribution in the tissue is very heterogeneous with only a subset of the cells having a much higher receptor concentration.

Staining for ir $\beta$ EP-like material was previously observed in the majority of interstitial Leydig cells (Bardin *et al.*, 1987). Since we found that only a subset of Leydig cells secrete ir $\beta$ EP, it may be that many of these cells have the POMC peptides but do not secrete them, assuming that the RHPA is sensitive enough to detect minute secretions from the cells. Possibly the ir $\beta$ EP in most Leydig cells is the product of the short POMC mRNA that translates a non-secretable protein.

Fabbri *et al.* (1990) demonstrated reversal of endogenous CRH inhibition of hCG-stimulated testosterone secretion by employing either the antagonist CRH-(9-41) or an antibody specific to CRH. This endogenous CRH inhibition was only seen in cultured Leydig cells and not in cells in suspension. They postulated that cell-to-cell interaction would favor the availability of secreted CRH to specific receptors. This postulate is in agreement with our finding in Leydig cell cultures, in which the antagonist CRH-(9-41) could not inhibit basal  $\beta$ EP secretion in the RHPAs where there is no Leydig cell to Leydig cell contact.

### **B. CRH effect on ir $\beta$ EP secretion in the rat testis *in vivo***

The current studies on the whole animal demonstrated a physiological relevance of CRH on  $\beta$ EP regulation. CRH was able to stimulate ir $\beta$ EP secretion in TIF in the pubertal rat but not in the adult, suggesting a developmental change in sensitivity to CRH. This finding in the study of the adult was in contrast to our finding in studies on cultured cells from adult rats, in which CRH was able to stimulate ir $\beta$ EP secretion. Perhaps this apparent contradiction reflects the fact that factors that may play a significant role in regulating the action of CRH in the intact adult testis are removed in dispersed cells. This observed difference between cells in culture and in the intact testis has precedent since Sharpe and coworkers (Sharpe et al., 1980) demonstrated differences between dispersed Leydig cells and cells in intact testes with respect to their sensitivity to gonadotropin-stimulation *in vitro* due to altered LH receptor numbers. In addition, arginine vasopressin was able to stimulate testosterone secretion in cell cultures from adult testis, but had no local effect *in vivo* (Sharpe et al., 1987). Moreover, *in vivo*, the competitive antagonist CRH-(9-41) acted as a weak agonist, in contrast to our *in vitro* system. These results suggest that experimental manipulation as well as environmental conditions can affect Leydig cell sensitivity and response to certain agents.

The observed action of CRH and its antagonist *in vitro* versus *in vivo* system demonstrates the necessity of whole animal experiments. Culture systems may reveal the existence of specific functional receptors in cells but do not provide information about the direction or magnitude of hormone action in the intact organ.

We observed that, in the pubertal animals, the antagonist CRH-(12-41) when added with CRH, was able to decrease ir $\beta$ EP levels in TIF from controls, indicating the presence of an endogenous CRH-like peptide that is able to increase ir $\beta$ EP levels in TIF of the pubertal rat testis. It is not known what factor(s) contribute to altered responsiveness of CRH during development.

TIF is the only vehicle for hormone transport into the testis and between testicular compartments (Sharpe et al., 1983a). Experimentally, TIF provides a simple means of sampling the intratesticular environment and measuring factors that are believed to be of importance as intratesticular communicators or regulators (Sharpe et al., 1983b). TIF is also an index of changes in capillary wall permeability which are important in the regulation of the energy and uptake of important hormones in the testis. Sharpe and coworkers reported changes in TIF volume after subcutaneous LH or hCG administration (Sharpe et al., 1983b), while Valenca and coworkers reported TIF volume changes after intratesticular administration of LHRH and LH (Valenca et al., 1986). In our experiments, CRH did not affect TIF volume, indicating that this peptide does not play a role on capillary wall permeability in testis.

### C. Pituitary-like POMC mRNA in the rat testis

The demonstrated presence of the long pituitary-like POMC mRNA in rat testis as well as in rat Leydig cells suggest that this transcript may be the message that encodes the POMC prohormone and hence the ir $\beta$ EP that is secreted into TIF in the intact testis and into the media in cell culture systems. It is still possible that tissues

such as the testis that contain the short POMC transcript have different processing enzymes as well as packaging requirements so that POMC-derived peptides can still be able to be stored in vesicles and be secreted in a regulated manner.

#### D. Temperature effect on the action of CRH

Maintenance of testicular temperature is essential for normal steroidogenesis and spermatogenesis. Results of the current study revealed a temperature-dependent difference in CRH dose-responsiveness of TM3 cells, a testicular Leydig cell line. This difference was not restricted to the Leydig cell line since AtT20 cells, a pituitary cell line, showed similar behavior. These results suggest that CRH receptors or post-receptor mechanisms may be sensitive to small changes in temperature. In the mature rat, FSH and hCG receptor number, and testosterone production decrease after cryptorchidectomy (Huhtaniemi et al., 1984; Sirvent et al., 1989). Namiki and coworkers (Namiki et al., 1987) investigated the influence of temperature on the functions of Leydig and Sertoli cells of testes from men with varicocele (scrotal temperature is elevated). hCG and FSH receptor levels were not different from men without varicocele, nor was testosterone concentrations in the testes. They also conducted experiments on human testicular organ culture at 33°C and 37°C and found no differences from controls. These studies suggest species differences. Our observations on the sensitivity of mouse cells to CRH at different temperatures could be species related.

In our studies, the EC<sub>50</sub> of CRH ( $1 \times 10^{-10}$  M) at 34°C was within the range of the

$K_d$  of CRH ( $1.3 \times 10^{-10}$  M) in Leydig cells, while the  $EC_{50}$  at  $37^\circ\text{C}$  was  $1 \times 10^{-9}$  M, suggesting that  $34^\circ\text{C}$  may be the optimum temperature for the function of CRH in testicular cells. Whether this phenomenon occurs in intact testis is not yet known.

Using immunocytochemistry, Yoon et al (1988) found irCRH-like peptide in interstitial and germ cells, while Audhya and coworkers (Audhya et al., 1989) detected irCRH-like peptide in Leydig cells but in no other cells in the testis. The reason for this discrepancy is not clear but could be due to differences in the CRH antibodies used.

#### E. Localization of CRH mRNA in the rat testis

We determined the possible source of CRH peptide in the testis by using a non-radioactive *in situ* hybridization technique to localize CRH mRNA. Audhya and coworkers (1987), Yoon and coworkers (1988), and Fabbri and coworkers (1990) documented the presence of immunoreactive CRH-like peptide in Leydig cells. We predicted that interstitial cells would be the predominant source of CRH mRNA. To our surprise, the digoxigenin-labelled CRH riboprobe in our studies intensely stained spermatogonia, spermatocytes, and spermatids in the tubules. Interstitial cells were not a prominently stained cell population. These results suggest that the primary site of CRH mRNA is germ cells. The irCRH detected in Fabbri and coworkers' preparations (1990) is approximately 0.24 ng/testis, assuming that there are approximately 10 million Leydig cells/testis. This value is approximately 300-fold lower than the amount of extractable CRH-like peptide in whole rat testis reported

by Yoon *et al.* (1988). These documentations suggest that non-Leydig cells are the major source of CRH. It is possible that a Leydig cell population contains low abundance CRH mRNA level that encodes for a CRH-like peptide in low amounts; therefore, our digoxigenin detection method was not sensitive enough to detect it.

Since CRH mRNA was found in germ cells and Yoon and coworkers (1988) documented the presence of irCRH-like peptide in these cells, it is conceivable that a CRH-like peptide is synthesized in germ cells. We speculate that this CRH-like peptide may affect POMC system in spermatocytes and spermatogonia, in an autocrine/paracrine fashion since these germ cells have the capacity to synthesize POMC (Cheng *et al.*, 1985, Gizang-Ginsberg *et al.*, 1985). Moreover, whether a CRH-like peptide whose origin is from germ cells, could be transported into the interstitium through some mechanism, is not known. Few peptides such as LHRH-like peptide and inhibin, presumed to be synthesized in tubular Sertoli cells, have been shown to act on interstitial Leydig cells to stimulate testosterone secretion (Sharpe *et al.*, 1981; Bardin *et al.*, 1990). These documentations do not address the question of how these peptides could be transported from the tubules into the interstitium. Since these peptides are hydrophylic, they cannot passively transverse membranes. Active transport mechanisms between testicular tubules and interstitium have not been studied to date.


It is well established that the major function of Leydig cells is to synthesize and secrete testosterone, the necessary steroid for normal spermatogenesis and fertility.

Ulisse and coworkers demonstrated that CRH alone had no effect on testosterone secretion but that it inhibited LH-stimulated testosterone release from cultured Leydig cells (Ulisse et al., 1989). Unpublished data in our laboratory on the effect of CRH on basal testosterone production in culture confirms this finding. Some peptides have been found to stimulate steroidogenesis, such as vasopressin (Kasson et al., 1986), inhibin and interleukin-1 (Verhoeven et al., 1988; Franchimont et al., 1989), while other peptides such as activin (Bardin et al., 1990), interleukin-2 (Guo et al., 1990) and epidermal growth factor (Bellve et al., 1989), inhibit steroidogenesis in culture systems. Therefore, the action and interaction of several locally produced peptides may be important modulators of testosterone secretion.


In conclusion, we clearly established that CRH is a local direct regulator of  $\beta$ EP secretion in the pubertal rat testis. The action of CRH is under developmental and, at least in culture, under thermal control. The factors contributing to a possible CRH short-loop regulation of testicular function are not known.


## VII. APPENDIX

## CRH GENE



# POMC GENE



**RHPA**

Drawn by Wing Chiu

**RHPA is complement mediated lysis of proteinated ovine red blood cells (oRBC) in the presence of antibody-antigen complex.**

## VIII. BIBLIOGRAPHY

Adashi EY, Tucker EM, Hsueh AJW (1984) Direct regulation of rat testicular steroidogenesis by neurohypophysial hormones. *J Biol Chem* 259:5440

Affolter HU, Reisine T (1985) Corticotropin releasing factor increases proopiomelanocortin messenger RNA in mouse anterior pituitary tumor cells. *J Biol Chem* 260:15477

Anakwe OO, Murphy PR, Moger WH (1985) Characterization of  $\beta$ -adrenergic binding sites on rodent Leydig cells. *Biol Reprod* 33:815

Antoni FA (1986) Hypothalamic control of adrenocorticotropin secretion: advances since the discovery of 41-residue corticotropin-releasing factor. *Endocr Rev* 7:351

Audhya T, Hollander CS, Schlesinger DH, Hutchinson B (1989) Structural characterization and localization of corticotropin-releasing factor in testis. *Biochim Biophys Acta* 995:10

Barbarino A, De Marinis L, Tofani A, Della Casa S, D'Amico C, Mancini A, Corsello SM, Sciuto R, Barini A (1989) Corticotropin-releasing hormone inhibition of gonadotropin release and the effect of opioid blockade. *J Clin Endocrinol Metab* 68:523

Barbarino A, De Marinis L, Tofani A, Della Casa S, D'Amico C, Mancini A, Maria Corsello S, Sciuto R, Barini A (1989) Corticotropin-releasing hormone inhibition of gonadotropin release and the effect of opioid blockade. *J Clin Endocrinol Metab* 68:523

Bardin CW, Chen CLC, Morris PL, Gerendai I, Boitani C, Liotta AS, Margioris A, Krieger DT (1987) Proopiomelanocortin-derived peptides in testis, ovary, and tissues of reproduction. *Recent Prog Horm Res* 43:1

Bardin CW, Morris PL, Shaha C, Feng ZM, Rossi V, Vaughan J, Vale WW, Voglmayr J, Chen CLC (1990) Inhibin structure and function in the testis. *Ann N Y Acad Sci* 564:10

Bellve AR, Zheng W (1989) Growth factors as autocrine and paracrine modulators of male gonadal functions. *J Reprod Fert* 85:771

Bergh A (1982) Local differences in Leydig cell morphology in the adult rat

testis: evidence for a local control of Leydig cells by adjacent seminiferous tubules. *Int J Androl* 5:325

Bergh A, Damber JE, Huhtaniemi I (1987) Intratesticular steroids and gonadotrophin receptor concentrations in the testes of immature unilaterally cryptorchid rats. *Int J Androl* 10:803

Bhasin S, Krummen LA, Swerdloff RS, Morelos BS, Kim WH, DiZerega GS, Ling N, Esch F, Shimasaki S, Toppari J (1989) Stage dependent expression of inhibin  $\alpha$  and  $\beta$ -B subunits during the cycle of the rat seminiferous epithelium. *Endocrinology* 124:987

Blackshaw AW, Massey PF (1978) The effect of cryptorchidism on the quantitative histology, histochemistry and hydrolytic enzyme activity of the rat testis. *Aust J Biol Sci* 31:53

Boitaini C, Farini D, Bardin CW, Stefanini M (1986) Melanocyte-stimulating-hormone may be a local modulator in the testis. In: Stefanini M, Conti M, Geremia R, Ziparo E (eds) *International Congress Series 716: Molecular and Cellular Endocrinology of the Testis*. Elsevier Science Publishers, The Netherlands, pages 37-48

Chase DJ, Payne AH (1983) Changes in Leydig cell function during sexual maturation in the mouse. *Biol Reprod* 29:1194

Chen CLC (1988) Expression and regulation of the proopiomelanocortin Gene and its physiological function in reproductive tissues. In: Martini L, Ganong WF (eds) *Frontiers in Neuroendocrinology*, vol 10. Raven Press, Ltd., New York, pages 99-116

Chen CLC, Madigan MB (1987) Regulation of testicular proopiomelanocortin gene expression. *Endocrinology* 121:590

Chen CLC, Mather JP, Morris PL, Bardin CW (1984) Expression of pro-opiomelanocortin-like gene in the testis and epididymis. *Biochemistry* 81:5672

Cheng MC, Clements JA, Smith AI, Lolait SJ, Funder JW (1985) N-acetyl endorphin in rat spermatogonia and primary spermatocytes. *J Clin Invest* 75:832

Chowdhury AK, Steinberger E (1964) A quantitative study of the effect of heat on germinal epithelium of rat testes. *Am J Anat* 115:509

Chowdhury AK, Steinberger E (1970) Early changes in the germinal epithelium of rat testes following exposure to heat. *J Reprod Fert* 22:205

Cicero TJ, Adams ML, O'Connor LH, Nock B (1989) *In vivo* evidence for a direct effect of naloxone on testicular steroidogenesis in the male rat. *Endocrinology* 125:957

Clark AJL, Lavender PM, Coates P, Johnson MR, Rees LH (1990) *In vitro* and *in vivo* analysis of the processing and fate of the peptide products of the short proopiomelanocortin mRNA. *Mol Endocrinol* 4:1737

Damber JE, Bergh A, Stelstam G, Sodergard R (1983) Estrogen receptor and aromatase activity in the testes of the unilateral cryptorchid rat. *Arch Androl* 11:259

Davis JR, Firlit CF (1966) The germinal epithelium of cryptorchid testes experimentally induced in prepubertal and adult rats. *Fert Steril* 17:187

DeBold CR, Nicholson WE, Orth DN (1988) Immunoreactive proopiomelanocortin (POMC) peptides and POMC-like messenger ribonucleic acid are present in many nonpituitary tissues. *Endocrinology* 122:2648

De Souza EB, Nemeroff CB (eds) (1985) *Corticotropin-releasing factor: basic and clinical studies of a neuropeptide*. CRC, Boca Raton, Florida

Douglas J, Cox B, Quinn B, Civelli O, Herbert E (1987) Expression of the prodynorphin gene in male and female mammalian reproductive tissues. *Endocrinology* 120:707

Drouin J, Chamberland M, Charron J, Jeannotte L, Nemer M (1985) Structure of the rat pro-opiomelanocortin (POMC) gene. *FEBS* 193:54

Dunn AJ, Berridge CW (1989) Is corticotropin-releasing factor a mediator of stress responses? *Ann N Y Acad Sci* 579:183

Eipper BA, Mains RE (1980) Structure and biosynthesis of pre-adreocorticotropin/endorphin and related peptides. *Endocr Rev* 1:1

Eskeland NL, Lugo DI, Pintar JE, Schachter BS (1989) Stimulation of  $\beta$ -endorphin secretion by corticotropin-releasing factor in primary rat Leydig cell cultures. *Endocrinology* 124:2914

Evans CJ, Erdelyi E, Weber E, Barchas JD (1983) Identification of pro-opiomelanocortin-derived peptides in the human adrenal medulla. *Science*

221:957

Fabbri A (1990) The role and regulation of testicular opioids. In: Journal Club: TEM. Elsevier Science Publishing Co., Inc., New York, pages 117-120

Fabbri A, Jannini EA, Gnessi L, Ulisse S, Moretti C, Isidori A (1989) Neuroendocrine control of male reproductive function. The opioid system as a model of control at multiple sites. *J Steroid Biochem* 32:145

Fabbri A, Knox G, Buczko E, Dufau ML (1988)  $\beta$ -Endorphin production by the fetal Leydig cell: regulation and implications for paracrine control of Sertoli cell function. *Endocrinology* 122:749

Fabbri A, Tinajero JC, Dufau ML (1990) Corticotropin-releasing factor is produced by rat Leydig cells and has a major local antireproductive role in the testis. *Endocrinology* 127:1541

Fabbri A, Tsai-Morris CH, Luna S, Fraioli F, Dufau ML (1985) Opiate receptors are present in the rat testis. Identification and localization in Sertoli cells. *Endocrinology* 117:2544

Feingold E, Seshadri SB, Tretiak OJ (1986) Hardware and software design considerations in engineering and image processing workstation: autoradiographic analysis with DUMAS and the BRAIN autoradiograph analysis software package. In: McEachron DL (ed), vol 2., Karger, Basel, 175

Franchimont P, Hazee-Hagelstein MT, Jasper JM, Charlet-Renard C, Demoulin A (1989) Inhibin and related peptides: mechanisms of action and regulation of secretion. *J Steroid Biochem* 32:193

Fujisawa M, Matsumoto O, Kamidono S, Hirose F, Kojima K, Yoshida S (1988) Changes of enzymes involved in DNA synthesis in the testes of cryptorchid rats. *J Reprod Fert* 84:123

Garrett JE, Douglass JO (1989) Human chorionic gonadotropin regulates expression of the proenkephalin gene in adult rat Leydig cells. *Mol Endocrinol* 3:2093

Gieno M, Chrousos GP, Margioris AN (1987) Corticotropin releasing hormone gene is expressed in human placenta. *Biochem Biophys Res Comm* 148:1208

Gizang-Ginsberg E, Wolgemuth DJ (1985) Localization of mRNAs in mouse testes by *in situ* hybridization: distribution of  $\alpha$ -tubulin and developmental

stage specificity of pro-opiomelanocortin transcripts. *Dev Biol* 111:293

Glembotski CG (1981) Subcellular fractionation studies on the post-translational processing of pro-adrenocorticotrophic hormone/endorphin in rat intermediate pituitary. *J Biol Chem* 256:7433

Gumbiner B, Kelly RB (1981) Secretory granules of anterior pituitary cell line, AtT20, contain only mature forms of corticotropin and  $\beta$ -lipotropin. *Proc Natl Acad Sci* 78:318

Gumbiner B, Kelly RB (1982) Two distinct intracellular pathways transport secretory and membrane glycoproteins to the surface of pituitary tumor cells. *Cell* 28:51

Guo H, Calkins JH, Sigel MM, Lin T (1990) Interleukin-2 is a potent inhibitor of Leydig cell steroidogenesis. *Endocrinology* 127:1234

Hedger MP, Eddy EM (1986) Monoclonal antibodies against rat Leydig cell surface antigen. *Biol Reprod* 35:1309

Hedger MP, Eddy EM (1987) The heterogeneity of isolated adult rat Leydig cells separated on Percoll density gradients: an immunological, cytochemical, and functional analysis. *Endocrinology* 121:1824

Hinegardner RT (1971) An improved fluorometric assay for DNA. *Anal Biochem* 39:197

Hotta Y, Fujisawa M, Tabata S, Stern H, Yoshida S (1988) The effect of temperature on recombinant activity in testes of rodents. *Exp Cell Res* 178:163

Huhtaniemi I, Bergh A, Nikula H, Damber JE (1984) Differences in the regulation of steroidogenesis and tropic hormone receptors between the scrotal and abdominal testes of unilaterally cryptorchid adult rats. *Endocrinology* 115:550

Huhtaniemi IT, Katikineni M, Catt KJ (1981) Regulation of luteinizing-hormone-receptors and steroidogenesis in the neonatal rat testis. *Endocrinology* 109:588

Huhtaniemi IT, Nozu K, Warren DW, Dufau ML, Catt KJ (1982) Acquisition of regulatory mechanisms for gonadotropin receptors and steroidogenesis in the maturing rat testis. *Endocrinology* 111:1711

Imaki T, Nahon JL, Sawchenko PE, Vale W (1989) Widespread expression of corticotropin-releasing factor messenger RNA and immunoreactivity in the rat olfactory bulb. *Brain Res* 496:35

Iturriza FC, Irusta O (1979) Hyperplasia of the interstitial cells of the testis in experimental cryptorchidism. *Acta Physiol Lat Am* 19:236

Ivell R, Furuya K, Brackmann B, Dawood Y, Khan-Dawood F (1990) Expression of the oxytocin and vasopressin genes in human and baboon gonadal tissues. *Endocrinology* 127:2990

Jeannotte L, Burbach JPH, Drouin J (1987) Unusual proopiomelanocortin ribonucleic acids in extrapituitary tissues: intronless transcripts in testes and long poly(A) tails in hypothalamus. *Mol Endocrinol* 1:749

Jegou B, Laws AO, De Kretser DM (1983) The effect of cryptorchidism and subsequent orchidopexy on testicular function in adult rats. *J Reprod Fert* 69:137

Jitendra RD, Eiden LE, Eskay RL (1985) Corticotropin-releasing factor binding to peripheral tissue and activation of the adenylate cyclase-adenosine 3'5'-monophosphate system. *Endocrinology* 116:2152

Juniewicz PE, Keeney DS, Ewing LL (1988) Effect of adrenocorticotropin and other proopiomelanocortin-derived peptides on testosterone secretion by the *in vitro* perfused testis. *Endocrinology* 122:891

Kasson BG, Hsueh AJW (1986) Arginine vasopressin as an intragonadal hormone in Brattleboro rats; presence of a testicular vasopressin-like peptide and functional receptors. *Endocrinology* 118:23

Keeping HS, Winters SJ, Attardi B, Troen P (1990) Developmental changes in testicular inhibin and androgen-binding protein during sexual maturation in the cynomolgus monkey, *Macaca fascicularis*. *Endocrinology* 126:2858

Kilpatrick DL, Millette CF (1986) Expression of proenkephalin messenger RNA by mouse spermatogenic cells. *Proc Natl Acad Sci* 83:5015

Knotts LK, Glass JD (1988) Effects of photoperiod, beta-endorphin, and naloxone on *in vitro* secretion of testosterone in white-footed mouse testes. *Biol Reprod* 39:205

Lacaze-Masmonteil T, De Keyser Y, Luton JP, Kahn A, Bertagna X (1987) Characterization of proopiomelanocortin transcripts in human nonpituitary

tissues. *Proc Natl Acad Sci* 84:7261

Leblond CP, Clermont Y (1952) Definition of the stages of the cycle of the seminiferous epithelium in the rat. *Annal N Y Acad Sci* 55:548

Lebouille JLM, Burbach JPH, De Kloet ER, Rommerts FFG (1986)  $\beta$ -endorphin-generating endopeptidases: distribution in body tissues and cellular localization in rat testes. *Endocrinology* 118:372

Leroux P, Pelletier G (1984) Radioautographic study of binding and internalization of corticotropin-releasing factor by rat anterior pituitary corticotrophs. *Endocrinology* 114:14

Liotta AS, Yamaguchi H, Krieger DT (1981) Biosynthesis and release of  $\beta$ -endorphin-*N*-acetyl  $\beta$ -endorphin-(1-27)-like peptides by rat pituitary neurointermediate lobe: beta-endorphin is not further processed by anterior lobe. *J Neurosci* 1:585

Lundblad JR, Roberts JL (1988) Regulation of proopiomelanocortin gene expression in pituitary. *Endocr Rev* 9:135

Lunstra DD, Schanbacher BD (1988) Testicular function and Leydig cell ultrastructure in long-term bilaterally cryptorchid rams. *Biol Reprod* 38:211

Maidment NT, Brumbaugh DR, Rudolph VD, Erdelyi E, Evans CJ (1989) Microdialysis of extracellular endogenous opioid peptides from rat brain *in vivo*. *Neuroscience* 33:549

Maniatis T, Fritsch EF, Sambrook J (1989) *Molecular cloning-a laboratory manual*, second edn. Cold Spring Harbor Laboratory Press, New York

Margioris AN, Gieno M, Proptos P, Gold PW, Chrousos GP (1988) Corticotropin-releasing factor and oxytocin stimulate the release of placental proopiomelanocortin peptides. *J Clin Endocrinol Metab* 66:922

Mather JP (1980) Establishment and characterization of two distinct mouse testicular epithelial cell lines. *Biol Reprod* 23:243

Morris PL, Vale WW, Cappel S, Bardin CW (1988) Inhibin production by primary Sertoli cell-enriched cultures: regulation by follicle-stimulating hormone, androgens, and epidermal growth factor. *Endocrinology* 122:717

Nakamura M, Namiki M, Okuyama A, Koh E, Kondoh N, Takeyama M, Fujioka H, Nishimune Y, Matsumoto K, Matsuda M (1988) Optimal

temperature for synthesis of DNA, RNA and protein by human testes in vitro. *Arch Androl* 20:41

Nakane T, Audhya T, Kanie N, Hollander CS (1985) Evidence for a role of endogenous corticotropin-releasing factor in cold, ether, immobilization, and traumatic stress. *Proc Natl Acad Sci* 82:1247

Namiki M, Nakamura M, Okuyama A, Sonoda T, Nishimune Y, Takatsuka D, Matsumoto K (1987) Influence of temperature on the function of Sertoli and Leydig cells of human testes. *Fert Steril* 47:475

Orth JM (1986) FSH-induced Sertoli cell proliferation in the developing rat is modified by  $\beta$ -endorphin produced in the testis. *Endocrinology* 119:1876

Payne AH, Downing JR, Wong K (1980) Lutenizing hormone receptors and testosterone synthesis in two distinct populations of Leydig cells. *Endocrinology* 106:1424

Petraglia F, Sawchenko PE, Rivier J, Vale W (1987) Evidence for local stimulation of ACTH secretion by corticotropin-releasing factor in human placenta. *Nature* 328:717

Petraglia F, Sutton S, Vale W, Plotsky P (1987) Corticotropin-releasing factor decreases plasma luteinizing hormone levels in female rats by inhibiting gonadotropin-releasing hormone release into hypophysial-portal circulation. *Endocrinology* 120:1083

Pilsworth LM, Setchell BP (1981) Spermatogenic and endocrine functions of the testes of invertebrate and vertebrate animals. In: Burger H, De Kretser D (eds) *The Testis*. Raven Press, New York, pages 30-31

Pintar JE, Schachter BS, Herman AB, Durgerian S, Krieger DT (1984) Characterization and localization of proopiomelanocortin messenger RNA in the adult testis. *Science* 225:632

Purvis K, Clausen OPF, Ulvik NM, Hansson (1979) Functional and morphological characteristics of rat Leydig cells: effects of prepubertal and postpubertal hypophysectomy. In: Steinberger A, Steinberger E (eds) *Testicular Development, Structure and Function*. Raven Press, New York, 212-215

Risbridger GP, Kerr JB, De Kretser DM (1981) Evaluation of Leydig cell function and gonadotropin binding in unilateral and bilateral cryptorchidism: evidence for local control of Leydig cell function by the seminiferous tubule.

**Biol Reprod 24:534**

**Ritzen ME, Hansson V, French FS (1981) The Sertoli cell. In: Burger H, De Kretser D (eds) The Testis. Raven Press, New York, pages 185-186**

**Rivier C, Cajander S, Vaughan J, Hsueh AJW, Vale W (1988) Age-dependent changes in physiological action, content, and immunostaining of inhibin in male rats. Endocrinology 123:120**

**Rivier C, Rivier J, Vale W (1986) Stress-induced inhibition of reproductive functions: role of endogenous corticotropin-releasing factor. Science 231:607**

**Rivier C, Vale W (1984) Influence of corticotropin-releasing factor on reproductive functions in the rat. Endocrinology 114:914**

**Rivier J, Rivier C, Vale W (1984) Synthetic competitive antagonists of corticotropin-releasing factor: effect on ACTH secretion in the rat. Science 224:889**

**Rosendale BE, Jarrett DB, Robinson AG (1987) Identification of a corticotropin-releasing factor-binding protein in the plasma membrane of AtT-20 mouse pituitary tumor cells and its regulation by dexamethasone. Endocrinology 120:2357**

**Russel LD, Alger LE, Nequin LG (1987) Hormonal control of pubertal spermatogenesis. Endocrinology 120:1615**

**Shaha C, Liotta AS, Krieger DT, Bardin CW (1984) The ontogeny of immunoreactive  $\beta$ -endorphin in fetal, neonatal, and pubertal testes from mouse and hamster. Endocrinology 114:1584**

**Sharpe RM (1984) Intratesticular factors controlling testicular function. Biol Reprod 30:29**

**Sharpe RM, Cooper I (1983) Testicular interstitial fluid as a monitor for changes in the intratesticular environment in the rat. J Reprod Fert 69:125**

**Sharpe RM, Cooper I (1987) Comparison of the effects on purified Leydig cells of four hormones (oxytocin, vasopressin, opiates and LHRH) with suggested paracrine roles in the testis. J Endocrinol 113:89**

**Sharpe RM, Doogan DG, Cooper I (1983) Direct effects of a luteinizing hormone-releasing hormone agonist on intratesticular levels of testosterone and interstitial fluid formation in intact male rats. Endocrinology 113:1306**

Sharpe RM, Fraser HM, Cooper I, Rommerts FFG (1981) Sertoli-Leydig cell communication via an LHRH-like factor. *Nature* 290:785

Sharpe RM, Kerr JB, Cooper I, Bartlett JMS (1986) Paracrine control mechanisms in the testis. In: Stefanini M, Conti M, Geremia R, Ziparo E (eds) *Molecular and Cellular Endocrinology of the Testis*. Elsevier Science Publishers, The Netherlands, pages 15-26

Sharpe RM, Kerr JB, Maddocks S (1988) Evidence for a role of the Leydig cells in control of the intratesticular secretion of inhibin. *Mol Cell Endocrinol* 60:243

Sharpe RM, Maddocks S, Kerr JB (1990) Cell-cell interactions in the control of spermatogenesis as studied using Leydig cell destruction and testosterone replacement. *Am J Anat* 188:3

Sharpe RM, McNeilly AS (1980) Differences between dispersed Leydig cells and intact testes in their sensitivity to gonadotrophin-stimulation *in vitro* after alteration of LH-receptor numbers. *Mol Cell Endocrinol* 18:75

Shivers BD, Schachter BS, Pfaff DW (1989) *In Situ* hybridization for the study of gene expression in the brain. *Methods Enzymol* 124:496

Sirvent JJ, Bernat R, Tora JR, Navarro MA, Garcia B, Brunet J (1989) Postpubertal cryptorchism. *Eur Urol* 16:433

Smith PF, Luque EH, Neill JD (1986) Detection and measurement of secretion from individual neuroendocrine cells using a reverse hemolytic plaque assay. *Methods Enzymol* 124:443

Springer JE, Robbins E, Gwag BJ, Lewis ME, Baldino Jr F (1991) Non-radioactive detection of nerve growth factor (NGFR) mRNA in the rat brain using *in situ* hybridization histochemistry. *J Histochem Cytochem* (in press)

Syed V, Khan SA, Ritzen EM (1985) Stage-specific inhibition of interstitial cell testosterone secretion by rat seminiferous tubules *in vitro*. *Mol Cell Endocrinol* 40:257

Syed V, Shafiq A, Khan A, Ritzen EM (1985) Stage-specific inhibition of interstitial cell testosterone secretion by rat seminiferous tubules *in vitro*. *Mol Cell Endocrinol* 40:257

Tahri-Joutei A, Pointis G (1989) AVP receptors of mouse Leydig cells are regulated by LH and E<sub>2</sub> and influenced by experimental cryptorchidism. *FEBS*

254:189

Tahri-Joutei A, Pointis G (1989) Developmental changes in arginine vasopressin receptors and testosterone stimulation in Leydig cells. *Endocrinology* 125:605

Thompson BC, Seasholtz AF, Herbert E (1987) Rat corticotropin-releasing hormone gene: sequence and tissue-specific expression. *Mol Endocrinol* 1:363

Tooze J, Hollinshead M, Frank R, Burke B (1987) An antibody specific for an endoproteolytic cleavage site provides evidence that pro-opiomelanocortin is packaged into secretory granules in AtT20 cells before its cleavage. *J Cell Biol* 105:155

Tooze J, Tooze SA (1986) Clathrin-coated vesicular transport secretory proteins during the formation of ACTH-containing secretory granules in AtT20 cells. *J Cell Biol* 103:839

Tsong SD, Phillips D, Halmi N, Liotta AS, Margioris A, Bardin CW, Krieger DT (1982) ACTH and  $\beta$ -endorphin-related peptides are present in multiple sites in the reproductive tract of the male rat. *Endocrinology* 110:2204

Ulisse S, Fabbri A, Dufau ML (1989) Corticotropin-releasing factor receptors and actions in rat Leydig cells. *J Biol Chem* 264:2156

Ulrich A, Shine J, Chirgwin J, Pictet R, Tischler E, Rutter WJ, Goodman HM (1977) Rat insulin genes: construction of plasmids containing the coding sequences. *Science* 196:1313

Vale W, Spiess J, Rivier C, Rivier J (1981) Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and  $\beta$ -endorphin. *Science* 213:1394

Valenca MM, Negro-Vilar A (1986) Proopiomelanocortin-derived peptides in testicular interstitial fluid: characterization and changes in secretion after human chorionic gonadotropin or luteinizing hormone-releasing hormone analog treatment. *Endocrinology* 118:32

Verhoeven G, Cailleau J, Van Damme J, Billiau A (1988) Interleukin-1 stimulates steroidogenesis in cultured rat Leydig cells. *Mol Cell Endocrinol* 57:51

Vescovi PP, Gerra G, Pioli G, Pedrazzoni M, Maninetti L, Passeri M (1990) Circulating opioid peptides during thermal stress. *Horm Metabol Res* 22:44

**Wang AM, Doyle MV, Mark DF (1989) Quantitation of mRNA by the polymerase chain reaction. Proc Natl Acad Sci 86:9717**

**Webster E, De Souza E (1988) Corticotropin-releasing factor receptors in mouse spleen: identification, autoradiographic localization, and regulation by divalent cations and guanine nucleotides. Endocrinology 122:609**

**Wynn PC, Aguilera G, Morell J, Catt KJ (1983) Properties and regulation of high-affinity pituitary receptors for corticotropin-releasing factor. Biochem Biophys Res Comm 110:602**

**Yoon DJ, Sklar C, David R (1988) Presence of immunoreactive corticotropin-releasing factor in rat testis. Endocrinology 122:759**